WHO Drug Information, Vol. 28, No. 3, 2014                                                Recommended INN: List 72



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 72
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are
selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended
International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or
pharmacy.
Lists of Proposed (1–109) and Recommended (1–70) International Nonproprietary Names can be found in Cumulative List
No. 15, 2013 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 72
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)]
les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes
internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune
recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–109) et recommandées (1–70) dans
la Liste récapitulative No. 15, 2013 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 72
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4
(EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han
sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en
las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la
sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–109) y Recomendadas (1–70) se encuentran
reunidas en Cumulative List No. 15, 2013 (disponible sólo en CD-ROM).



                                                                                                                 379
Recommended INN: List 72                                                 WHO Drug Information, Vol. 28, No. 3, 2014




 Latin, English, French, Spanish:
 Recommended INN                    Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada




 abametapirum
 abametapir                                5,5'-dimethyl-2,2'-bipyridinyl

 abamétapir                                5,5'-diméthyl-2,2'-bipyridinyle

 abametapir                                5,5'-dimetil-2,2'-bipiridinilo

                                           C12H12N2

                                            H3 C
                                                        N



                                                            N
                                                                        CH3


 acidum bempedoicum
 bempedoic acid                            8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid

 acide bempédoïque                         acide 8-hydroxy-2,2,14,14-tétraméthylpentadécanedioïque

 ácido bempedoico                          ácido 8-hidroxi-2,2,14,14-tetrametilpentadecanodióco

                                           C19H36O5

                                            HO2C                                                 CO2H

                                               H3 C   CH3                OH              H 3C   CH3


 aclerastidum
 aclerastide                               [3-(L-2-aminohexanoic acid)]angiotensin II-(1-7)-peptide

 aclérastide                               [3-(acide L-2-aminohexanoïque)]angiotensine II-(1-7)-peptide

 aclerastida                               [3-(ácido L-2-aminohexanoico)]angiotensina II-(1-7)-péptido

                                           C42H64N12O11

                                            H Asp     Arg   Nle   Tyr    Ile   His   Pro OH
                                                                                     7


 aducanumabum #
 aducanumab                                immunoglobulin G1-kappa, anti-[Homo sapiens amyloid beta (Abeta,
                                           Aβ) peptide], Homo sapiens monoclonal antibody;
                                           gamma1 heavy chain (1-453) [Homo sapiens VH (IGHV3-33*01
                                           (93.90%) -(IGHD)-IGHJ6*03) [8.8.17] (1-124) -IGHG1*03 (CH1 (125-
                                           222), hinge (223-237), CH2 (238-347), CH3 (348-452), CHS K2>del
                                           (453)) (125-453)], (227-214')-disulfide with kappa light chain (1'-214')
                                           [Homo sapiens V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ4*01)
                                           [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (233-233'':236-236'')-
                                           bisdisulfide


380
WHO Drug Information, Vol. 28, No. 3, 2014                                                            Recommended INN: List 72




 aducanumab                                  immunoglobuline G1-kappa, anti-[Homo sapiens peptide amyloïde
                                             bêta (Abêta, Aβ)], Homo sapiens anticorps monoclonal;
                                             chaîne lourde gamma1 (1-453) [Homo sapiens VH (IGHV3-33*01
                                             (93.90%) -(IGHD)-IGHJ6*03) [8.8.17] (1-124) -IGHG1*03 (CH1 (125-
                                             222), charnière (223-237), CH2 (238-347), CH3 (348-452), CHS
                                             K2>del (453)) (125-453)], (227-214')-disulfure avec la chaîne légère
                                             kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-39*01 (100.00%) -
                                             IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (233-
                                             233'':236-236'')-bisdisulfure

 aducanumab                                  inmunoglobulina G1-kappa, anti-[péptido amiloide beta de Homo
                                             sapiens (Abeta, Aβ)], Homo sapiens anticuerpo monoclonal;
                                             cadena pesada gamma1 (1-453) [Homo sapiens VH (IGHV3-33*01
                                             (93.90%) -(IGHD)-IGHJ6*03) [8.8.17] (1-124) -IGHG1*03 (CH1 (125-
                                             222), bisagra (223-237), CH2 (238-347), CH3 (348-452), CHS
                                             K2>del (453)) (125-453)], (227-214')-disulfuro con la cadena ligera
                                             kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-39*01 (100.00%) -
                                             IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (233-
                                             233'':236-236'')-bisdisulfuro


                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVESGGG VVQPGRSLRL SCAASGFAFS                  SYGMHWVRQA       PGKGLEWVAV        50
                                             IWFDGTKKYY TDSVKGRFTI SRDNSKNTLY                  LQMNTLRAED       TAVYYCARDR       100
                                             GIGARRGPYY MDVWGKGTTV TVSSASTKGP                  SVFPLAPSSK       STSGGTAALG       150
                                             CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV                  LQSSGLYSLS       SVVTVPSSSL       200
                                             GTQTYICNVN HKPSNTKVDK RVEPKSCDKT                  HTCPPCPAPE       LLGGPSVFLF       250
                                             PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV                  KFNWYVDGVE       VHNAKTKPRE       300
                                             EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV                  SNKALPAPIE       KTISKAKGQP       350
                                             REPQVYTLPP SREEMTKNQV SLTCLVKGFY                  PSDIAVEWES       NGQPENNYKT       400
                                             TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF                  SCSVMHEALH       NHYTQKSLSL       450
                                             SPG                                                                                 453

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIQMTQSPSS LSASVGDRVT ITCRASQSIS                  SYLNWYQQKP       GKAPKLLIYA 50
                                             ASSLQSGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       SYSTPLTFGG 100
                                             GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-96          151-207       268-328   374-432
                                                                   22''-96'' 151''-207'' 268''-328'' 374''-432''
                                             Intra-L (C23-C104) 23'-88'        134'-194'
                                                                   23'''-88''' 134'''-194'''
                                             Inter-H-L (h 5-CL 126) 227-214' 227''-214'''
                                             Inter-H-H (h 11, h 14) 233-233'' 236-236''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             304, 304''




 alpelisibum
                                                     1
 alpelisib                                   (2S)-N -{4-methyl-5-[1-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-
                                             4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide
                                                     1
 alpélisib                                   (2S)-N -{4-méthyl-5-[1-(1,1,1-trifluoro-2-méthylpropan-2-yl)pyridin-
                                             4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide
                                                     1
 alpelisib                                   (2S)-N -{4-metil-5-[1-(1,1,1-trifluoro-2-metilpropan-2-il)piridin-4-il]-
                                             1,3-tiazol-2-il}pirrolidina-1,2-dicarboxamida




                                                                                                                                        381
Recommended INN: List 72                                  WHO Drug Information, Vol. 28, No. 3, 2014


                           C19H22F3N5O2S
                                                            O        O
                                                                 H
                                                    HN
                                                             N           NH2
                            H3C    CH3          S
                                                      N
                           F3C
                                     N              CH3



 andexanetum alfa #
 andexanet alfa            des-(6-39)-human blood-coagulation factor X light chain (98-108')-
                           disulfide with [185'-alanine (S>A)]human activated factor Xa heavy
                           chain, produced in Chinese hamster ovary (CHO) cells (glycoform
                           alfa)

 andexanet alfa            (98-108')-disulfure entre la dès-(6-39)-chaîne légère du facteur X de
                           coagulation humain et la [185'-alanine (S>A)]chaîne lourde du
                           facteur Xa activé de coagulation humain glycosylé, produit par les
                           cellules ovariennes de hamster chinois (CHO) (glycoforme alfa)

 andexanet alfa            (98-108')-disulfuro entre la des-(6-39)-cadena ligera del factor X de
                           coagulación humano y la [185'-alanina (S>A)]cadena pesada del
                           factor Xa activado de coagulación humano glicosilado, producido por
                           cultivo de células ováricas de hamster chino (CHO) (glicoforma alfa)


                           Light chain / Chaîne légère / Cadena ligera
                           ANSFLFWNKY KDGDQCETSP CQNQGKCKDG LGEYTCTCLE GFEGKNCELF 50
                           TRKLCSLDNG DCDQFCHEEQ NSVVCSCARG YTLADNGKAC IPTGPYPCGK 100
                           QTLER                                                  105

                           Heavy chain / Chaîne lourde / Cadena pesada
                           IVGGQECKDG ECPWQALLIN EENEGFCGGT ILSEFYILTA                  AHCLYQAKRF      50'
                           KVRVGDRNTE QEEGGEAVHE VEVVIKHNRF TKETYDFDIA                  VLRLKTPITF      100'
                           RMNVAPACLP ERDWAESTLM TQKTGIVSGF GRTHEKGRQS                  TRLKMLEVPY      150'
                           VDRNSCKLSS SFIITQNMFC AGYDTKQEDA CQGDAGGPHV                  TRFKDTYFVT      200'
                           GIVSWGEGCA RKGKYGIYTK VTAFLKWIDR SMKTRGLPKA                  KSHAPEVITS      250'
                           SPLK                                                                         254'

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes
                           disulfuro
                           7'-12' 16-27 21-36        27'-43'     38-47    55-66
                           62-75 77-90 98-108' 156'-170' 181'-209'

                           Modified residue / Résidu modifié / Resto modificado
                                        D                     H NH2
                                       29
                                                    HO2C
                                                                    CO2H
                            (3R)-3-hydroxyAsp
                                                         HO H
                           Glycosylation sites (* confirmed) / Sites de glycosylation (* confirmé) / Posiciones de
                           glicosilación (* confirmada)
                           Ser-56 Ser-72 Ser-76 Thr-82 *Thr-249'




 apabetalonum
 apabetalone               2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxyquinazolin-
                           4(3H)-one

 apabétalone               2-[4-(2-hydroxyéthoxy)-3,5-diméthylphényl]-5,7-diméthoxyquinazolin-
                           4(3H)-one

 apabetalona               2-[4-(2-hidroxietoxi)-3,5-dimetilfenil]-5,7-dimetoxiquinazolin-
                           4(3H)-ona




382
WHO Drug Information, Vol. 28, No. 3, 2014                                                  Recommended INN: List 72




                                             C20H22N2O5
                                                                         CH3
                                                                               O
                                                                                         OH
                                             H3CO              N
                                                                               CH3
                                                                   NH

                                                        OCH3 O




 apatorsenum
 apatorsen                                   all-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-
                                             methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-
                                             thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-
                                             deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-
                                             (3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-
                                             thioguanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-5-
                                             methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-
                                             deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-
                                             deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-
                                             (3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-
                                             methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-
                                             thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-
                                             O-(2-methoxyethyl)-5-methyluridine

 apatorsen                                   tout-P-ambo-2'-O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-
                                             méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-
                                             thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-
                                             déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-
                                             (3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-déoxy-P-
                                             thioguanylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-déoxy-5-
                                             méthyl-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-
                                             déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-
                                             déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguanylyl-
                                             (3'→5')-2'-déoxy-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-
                                             méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-
                                             thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-
                                             O-(2-méthoxyéthyl)-5-méthyluridine

 apatorsén                                   todo-P-ambo-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-
                                             metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-
                                             (3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-2'-desoxi-5-metil-P-
                                             tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-5-metil-P-
                                             tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-
                                             tioguanilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-
                                             tioguanilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-P-tiotimidilil-
                                             (3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-
                                             (3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-
                                             tiouridilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-
                                             (2-metoxietil)-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metiluridina




                                                                                                                        383
Recommended INN: List 72                                                                    WHO Drug Information, Vol. 28, No. 3, 2014


                           C224H304N79O116P19S19

                           (3'5')d(P-thio)(rG-rG-rG-rA-mC-G-mC-G-G-mC-G-
                           mC-T-mC-G-G-rU-rC-rA-rU)
                           Modified nucleosides / Nucléosides modifiés / Nucleosidos modificados
                           A                                           N                                                O       N                   NH2
                                                                                                    OH
                                                       N                        NH2
                           OH                                                                                       O       N
                                                                                                                                                    CH3
                                           O               N           N
                                                                                                                                    dmC
                                                                                                    HO
                                                                           OCH3
                             HO                    O                                                            C O             N                   NH2
                                                                                                    OH
                                                                                                                    O       N
                                                                                                                                                    CH3
                                                                                                                                            OCH3
                           G                       H 2N
                                                                                                    HO                  O
                                                                       NH
                                                       N                        O                               U               H
                                                                                                                        O       N                   O
                           OH                                                                       OH
                                           O               N           N                                            O       N
                                                                                                                                                    CH3
                                                                           OCH3                                                             OCH3
                            HO                     O                                                HO                  O



 astodrimerum
                               2       6                   2       6                2   6                   2       6           2           6
 astodrimer                N ,N -bis{N ,N -bis[N ,N -bis(N ,N -bis{N ,N -bis[(3,6-
                           disulfonaphthalen-1-yloxy)acetyl]-L-lysyl}-L-lysyl)-L-lysyl]-L-lysyl}-
                             1
                           N -(diphenylmethyl)-L-lysinamide
                               2       6                   2       6                2   6                   2       6           2           6
 astodrimère               N ,N -bis{N ,N -bis[N ,N -bis(N ,N -bis{N ,N -bis[(3,6-
                           disulfonaphthalén-1-yloxy)acétyl]-L-lysyl}-L-lysyl)-L-lysyl]-L-lysyl}-
                             1
                           N -(diphénylméthyl)-L-lysinamide
                               2       6                   2       6                2   6                   2       6           2           6
 astodrímero               N ,N -bis{N ,N -bis[N ,N -bis(N ,N -bis{N ,N -bis[(3,6-
                           disulfonafthalen-1-iloxi)acetil]-L-lisil}-L-lisil)-L-lisil]-L-lisil}-
                             1
                           N -(difenilmetil)-L-lisinamida

                           C583H641N63O287S64

                                       A               A               A        A                       A           A           A               A
                                               K                            K                                   K                       K


                            A              K                                K           A       A               K                       K               A
                                   K                                                K               K                                               K
                                                               K                                                            K
                                   A                                                A               A                                            A
                                    A              A                                                                            A               A
                                           K                                                K                                           K
                                                                                K                       K
                                           K                                                NH                                          K               A
                           A
                                   K                                                                                                                K
                                                           K                                                                K
                                   A                                                                                                                A


                                           A               K                A                                   A           K               A
                                                   K                   K                                            K               K
                                                   A                   A                                            A               A
                                                                                                    A           =
                                   K               =                                                                            O               C
                                                                   H       NH
                                                                                                                                                O
                                   N                                       C
                                   H
                                                                           O                        HO3S                                        SO3H




384
WHO Drug Information, Vol. 28, No. 3, 2014                                                 Recommended INN: List 72


 batefenterolum
 batefenterol                                1-(3-{[2-chloro-4-({[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-
                                             1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)-
                                             5-methoxyphenyl]amino}-3-oxopropyl)piperidin-4-yl (1,1-biphenyl-
                                             2-yl)carbamate

 batéfentérol                                (1,1-biphényl-2-yl)carbamate de 1-(3-{[2-chloro-4-({[(2R)-2-hydroxy-
                                             2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)éthyl]amino}méthyl)-
                                             5-méthoxyphényl]amino}-3-oxopropyl)pipéridin-4-yle

 batefenterol                                (1,1-bifenil-2-il)carbamato de 1-(3-{[2-cloro-4-({[(2R)-2-hidroxi-
                                             2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil]amino}metil)-
                                             5-metoxifenil]amino}-3-oxopropil)piperidin-4-ilo

                                             C40H42ClN5O7

                                                                                 H
                                                                H3CO             N     O           O        O
                                                         H OH
                                                                 H
                                                                 N                         N           HN
                                                                                 Cl

                                             HO
                                                   HN

                                                        O

 bimekizumabum #
 bimekizumab                                 immunoglobulin G1-kappa, anti-[Homo sapiens IL17A (interleukin
                                             17A) and Homo sapiens IL17F (interleukin 17F)], humanized
                                             monoclonal antibody;
                                             gamma1 heavy chain (1-455) [humanized VH (Homo sapiens
                                             IGHV3-7*01 (88.70%) -(IGHD)-IGHJ1*01) [8.8.18] (1-125) -Homo
                                             sapiens IGHG1*01 (CH1 (126-223), hinge (224-238), CH2 (239-
                                             348), CH3 (349-453), CHS (454-455)) (126-455)], (228-214')-
                                             disulfide with kappa light chain (1'-214') [humanized V-KAPPA
                                             (Homo sapiens IGKV1-13*02 (80.00%) -IGKJ1*01) [6.3.9] (1'-107') -
                                             Homo sapiens IGKC*01 (108'-214')]; dimer (234-234":237-237")-
                                             bisdisulfide

 bimékizumab                                 immunoglobuline G1-kappa, anti-[Homo sapiens IL17A (interleukine
                                             17A) et Homo sapiens IL17F (interleukine 17F)], anticorps
                                             monoclonal humanisé;
                                             chaîne lourde gamma1 (1-455) [VH humanisé (Homo sapiens
                                             IGHV3-7*01 (88.70%) -(IGHD)-IGHJ1*01) [8.8.18] (1-125) -Homo
                                             sapiens IGHG1*01 (CH1 (126-223), charnière (224-238), CH2 (239-
                                             348), CH3 (349-453), CHS (454-455)) (126-455)], (228-214')-
                                             disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé
                                             (Homo sapiens IGKV1-13*02 (80.00%) -IGKJ1*01) [6.3.9] (1'-107') -
                                             Homo sapiens IGKC*01 (108'-214')]; dimère (234-234":237-237")-
                                             bisdisulfure

 bimekizumab                                 inmunoglobulina G1-kappa, anti-[Homo sapiens IL17A (interleukina
                                             17A) et Homo sapiens IL17F (interleukina 17F)], anticuerpo
                                             monoclonal humanizado;
                                             cadena pesada gamma1 (1-455) [VH humanizado (Homo sapiens
                                             IGHV3-7*01 (88.70%) -(IGHD)-IGHJ1*01) [8.8.18] (1-125) -Homo
                                             sapiens IGHG1*01 (CH1 (126-223), bisagra (224-238), CH2 (239-
                                             348), CH3 (349-453), CHS (454-455)) (126-455)], (228-214')-
                                             disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado
                                             (Homo sapiens IGKV1-13*02 (80.00%) -IGKJ1*01) [6.3.9] (1'-107') -
                                             Homo sapiens IGKC*01 (108'-214')]; dímero (234-234":237-237")-
                                             bisdisulfuro

                                                                                                                  385
Recommended INN: List 72                                    WHO Drug Information, Vol. 28, No. 3, 2014




                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  DYNMAWVRQA       PGKGLEWVAT        50
                           ITYEGRNTYY RDSVKGRFTI SRDNAKNSLY                  LQMNSLRAED       TAVYYCASPP       100
                           QYYEGSIYRL WFAHWGQGTL VTVSSASTKG                  PSVFPLAPSS       KSTSGGTAAL       150
                           GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA                  VLQSSGLYSL       SSVVTVPSSS       200
                           LGTQTYICNV NHKPSNTKVD KKVEPKSCDK                  THTCPPCPAP       ELLGGPSVFL       250
                           FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE                  VKFNWYVDGV       EVHNAKTKPR       300
                           EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK                  VSNKALPAPI       EKTISKAKGQ       350
                           PREPQVYTLP PSRDELTKNQ VSLTCLVKGF                  YPSDIAVEWE       SNGQPENNYK       400
                           TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV                  FSCSVMHEAL       HNHYTQKSLS       450
                           LSPGK                                                                               455

                           Light chain / Chaîne légère / Cadena ligera
                           AIQLTQSPSS LSASVGDRVT ITCRADESVR                  TLMHWYQQKP       GKAPKLLIYL 50
                           VSNSEIGVPD RFSGSGSGTD FRLTISSLQP                  EDFATYYCQQ       TWSDPWTFGQ 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          152-208       269-329   375-433
                                                 22''-96'' 152''-208'' 269''-329'' 375''-433''
                           Intra-L (C23-C104) 23'-88'        134'-194'
                                                 23'''-88''' 134'''-194'''
                           Inter-H-L (h 5-CL 126) 228-214' 228''-214'''
                           Inter-H-H (h 11, h 14) 234-234'' 237-237''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           305, 305''




 bococizumabum #
 bococizumab               immunoglobulin G2-kappa, anti-[Homo sapiens PCSK9 (proprotein
                           convertase subtilisin/kexin type 9, neural apoptosis-regulated
                           convertase 1, NARC1, NARC-1, proprotein convertase 9, PC9)],
                           humanized monoclonal antibody;
                           gamma2 heavy chain (1-444) [humanized VH (Homo sapiens
                           IGHV1-46*01 (90.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11]
                           (1-118) -Homo sapiens IGHG2*01 (CH1 (119-216), hinge (217-228),
                           CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS
                           (443-444)) (119-444)], (132-214')-disulfide with kappa light chain
                           (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-13*02
                           (91.00%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-
                           214')]; dimer (220-220":221-221":224-224":227-227")-
                           tetrakisdisulfide

 bococizumab               immunoglobuline G2-kappa, anti-[Homo sapiens PCSK9
                           (proprotéine convertase subtilisine/kexine type 9, convertase 1
                           régulée par l'apoptose neuronale, NARC1, NARC-1, proprotéine
                           convertase 9, PC9)], anticorps monoclonal humanisé;
                           chaîne lourde gamma2 (1-444) [VH humanisé (Homo sapiens
                           IGHV1-46*01 (90.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11]
                           (1-118) -Homo sapiens IGHG2*01 (CH1 (119-216), charnière (217-
                           228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442),
                           CHS (443-444)) (119-444)], (132-214')-disulfure avec la chaîne
                           légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-
                           13*02 (91.00%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                           (108'-214')]; dimère (220-220":221-221":224-224":227-227")-
                           tétrakisdisulfure




386
WHO Drug Information, Vol. 28, No. 3, 2014                                                           Recommended INN: List 72


 bococizumab                                 inmunoglobulina G2-kappa, anti-[Homo sapiens PCSK9 (proproteína
                                             convertasa subtilisina/kexina tipo 9, convertasa 1 regulada por la
                                             apoptosis neuronal, NARC1, NARC-1, proproteína convertasa 9,
                                             PC9)], anticuerpo monoclonal humanizado;
                                             cadena pesada gamma2 (1-444) [VH humanizada (Homo sapiens
                                             IGHV1-46*01 (90.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11]
                                             (1-118) -Homo sapiens IGHG2*01 (CH1 (119-216), bisagra (217-
                                             228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442),
                                             CHS (443-444)) (119-444)], (132-214')-disulfuro con la cadena ligera
                                             kappa (1'-214') [V-KAPPA humanizada (Homo sapiens IGKV1-13*02
                                             (91.00%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-
                                             214')]; dímero (220-220":221-221":224-224":227-227")-
                                             tetrakisdisulfuro


                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVQSGAE VKKPGASVKV SCKASGYTFT                  SYYMHWVRQA       PGQGLEWMGE        50
                                             ISPFGGRTNY NEKFKSRVTM TRDTSTSTVY                  MELSSLRSED       TAVYYCARER       100
                                             PLYASDLWGQ GTTVTVSSAS TKGPSVFPLA                  PCSRSTSEST       AALGCLVKDY       150
                                             FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSNFGTQTYT       200
                                             CNVDHKPSNT KVDKTVERKC CVECPPCPAP                  PVAGPSVFLF       PPKPKDTLMI       250
                                             SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE                  VHNAKTKPRE       EQFNSTFRVV       300
                                             SVLTVVHQDW LNGKEYKCKV SNKGLPSSIE                  KTISKTKGQP       REPQVYTLPP       350
                                             SREEMTKNQV SLTCLVKGFY PSDIAVEWES                  NGQPENNYKT       TPPMLDSDGS       400
                                             FFLYSKLTVD KSRWQQGNVF SCSVMHEALH                  NHYTQKSLSL       SPGK             444

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIQMTQSPSS LSASVGDRVT ITCRASQGIS                  SALAWYQQKP       GKAPKLLIYS 50
                                             ASYRYTGVPS RFSGSGSGTD FTFTISSLQP                  EDIATYYCQQ       RYSLWRTFGQ 100
                                             GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-96           145-201       258-318  364-422
                                                                    22''-96'' 145''-201'' 258''-318'' 364''-422''
                                             Intra-L (C23-C104) 23'-88'          134'-194'
                                                                    23'''-88''' 134'''-194'''
                                             Inter-H-L (CH1 10-CL 126)           132-214' 132''-214'''
                                             Inter-H-H (h 4, h 5, h 11, h 14) 220-220'' 221-221'' 224-224'' 227-227''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             294, 294''



 brincidofovirum
 brincidofovir                               3-(hexadecyloxy)propyl hydrogen ({(1S)-1-[(4-amino-2-oxopyrimidin-
                                             1(2H)-yl)methyl]-2-hydroxyethoxy}methyl)phosphonate

 brincidofovir                               ({(1S)-1-[(4-amino-2-oxopyrimidin-1(2H)-yl)méthyl]-
                                             2-hydroxyethoxy}methyl)hydrogénophosphonate de
                                             3-(hexadécyloxy)propyle

 brincidofovir                               ({(1S)-1-[(4-amino-2-oxopirimidin-1(2H)-il)metil]-
                                             2-hidroxietoxi}metil)hidrógenofosfonato de 3-(hexadeciloxi)propilo

                                             C27H52N3O7P

                                                      NH2

                                                 N

                                             O        N            O OH           H3C
                                                             O       P
                                                                         O               O
                                                 HO         H




                                                                                                                                       387
Recommended INN: List 72                                    WHO Drug Information, Vol. 28, No. 3, 2014


 canoctakinum #
 canoctakin                recombinant DNA derived, human interleukin 8 (CXCL8) mutein,
                           produced in Escherichia coli:
                           [44,48,97,98-tetra-L-lysine]human interleukin 8 precursor-(34-99)-
                           peptide

 canoctakine               mutéine de l'interleukine 8 humaine (CXCL8), produite dans
                           Escherichia coli à partir d'ADN recombinant:
                           [44,48,97,98-tétra-L-lysine]précurseur de l'interleukine 8 humaine-
                           (34-99)-peptide

 canoctakina               muteína de la interleukina 8 humana (CXCL8), producida en
                           Escherichia coli a partir de ADN recombinante:
                           [44,48,97,98-tetra-L-lisina]precursor de la interleukina 8 humana-(34-
                           99)-péptido

                           C340H565N99O94S4
                                                                                   CQCIKTY SKPKHPKKIK 50
                           ELRVIESGPH CANTEIIVKL SDGRELCLDP KENWVQRVVE KFLKRAKKS 99
                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           34-61 36-77



 censavudinum
 censavudine               1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-
                           5-methylpyrimidine-2,4(1H,3H)-dione

 censavudine               1-[(2R,5R)-5-éthynyl-5-(hydroxyméthyl)-2,5-dihydrofuran-2-yl]-
                           5-méthylpyrimidine-2,4(1H,3H)-dione

 censavudina               1-[(2R,5R)-5-etinil-5-(hidroximetil)-2,5-dihidrofuran-2-il]-
                           5-metilpirimidina-2,4(1H,3H)-diona

                           C12H12N2O4
                                                     H
                                             O       N      O

                                         O       N
                           HO                                CH3
                           HC

 cimaglerminum alfa #
 cimaglermin alfa          recombinant DNA derived glial growth factor 2(GGF2), produced in
                           Chinese hamster ovary (CHO) cells (glycoform alfa):
                           [253-L-glutamine(R>Q variant 009307)]human pro-neuregulin-1
                           membrane-bound isoform 9 precursor-(51-422)-peptide

 cimaglermine alfa         facteur de croissance 2 glial, produit par des cellules ovariennes de
                           hamster chinois (glycoforme alfa):
                           [253-L-glutamine(R>Q variant 009307)]précurseur de l'isoforme 9 de
                           la pro-neuréguline-1, se liant à la membrane, humain-(51-422)-
                           peptide obtenu par culture de cellules ovariennes d'hamster chinois
                           (CHO), glycoforme alfa

 cimaglermina alfa         factor de crecimiento glial 2, producido por células ováricas de
                           hamster chino (glicoforma alfa):
                           [253-L-glutamina(R>Q variante 009307)]precursor de la isoforma 9
                           de la pro-neuregulina-1, que se une a la membrana, humano-(51-
                           422)-péptido obtenido por cultivo de células ováricas de hamster
                           chino (CHO), glicoforma alfa




388
WHO Drug Information, Vol. 28, No. 3, 2014                                                            Recommended INN: List 72




                                              Sequence / Séquence /Ssecuencia
                                              GNEAAPAGAS VCYSSPPSVG SVQELAQRAA                  VVIEGKVHPQ       RRQQGALDRK       50
                                              AAAAAGEAGA WGGDREPPAA GPRALGPPAE                  EPLLAANGTV       PSWPTAPVPS       100
                                              AGEPGEEAPY LVKVHQVWAV KAGGLKKDSL                  LTVRLGTWGH       PAFPSCGRLK       150
                                              EDSRYIFFME PDANSTSRAP AAFRASFPPL                  ETGRNLKKEV       SRVLCKRCAL       200
                                              PPQLKEMKSQ ESAAGSKLVL RCETSSEYSS                  LRFKWFKNGN       ELNRKNKPQN       250
                                              IKIQKKPGKS ELRINKASLA DSGEYMCKVI                  SKLGNDSASA       NITIVESNAT       300
                                              STSTTGTSHL VKCAEKEKTF CVNGGECFMV                  KDLSNPSRYL       CKCPNEFTGD       350
                                              RCQNYVMASF YSTSTPFLSL PE                                                            372

                                              Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                              12-146 195-198 222-277 313-327 321-341 343-352

                                              Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                                              Asn-87 Asn-164 Asn-285 Asn-291 Asn-298




 cipargaminum
 cipargamin                                   (1'R,3'S)-5,7'-dichloro-6'-fluoro-3'-methyl-2',3',4',9'-
                                              tetrahydrospiro[indole-3,1'-pyrido[3,4-b]indol]-2(1H)-one

 cipargamine                                  (1'R,3'S)-5,7'-dichloro-6'-fluoro-3'-méthyl-2',3',4',9'-
                                              tétrahydrospiro[indole-3,1'-pyrido[3,4-b]indol]-2(1H)-one

 cipargamina                                  (1'R,3'S)-5,7'-dicloro-6'-fluoro-3'-metil-2',3',4',9'-tetrahidrospiro[indol-
                                              3,1'-pirido[3,4-b]indol]-2(1H)-ona

                                              C19H14Cl2FN3O

                                                                 H
                                                                 N
                                                                        O
                                                Cl                    NH
                                                        HN                  H
                                                                            CH3

                                               Cl

                                                       F



dapirolizumabum pegolum #
dapirolizumab pegol                          immunoglobulin Fab' G1-kappa pegylated, anti-[Homo sapiens
                                             CD40LG (CD40 ligand, CD40L, tumor necrosis factor ligand
                                             superfamily member 5, TNFSF5, tumor necrosis factor related
                                             activation protein, TRAP, CD154)], pegylated humanized monoclonal
                                             antibody;
                                             gamma1 heavy chain fragment VH-(CH1-hinge) (1-229) [humanized
                                             VH (Homo sapiens IGHV3-74*01 (76.50%) -(IGHD)-IGHJ1*01)
                                             [8.7.12] (1-118) -Homo sapiens IGHG1*01 (CH1 (119-216), hinge
                                             1-11 (217-227)) (119-227) -dialanyl (228-229)], (221-214')-disulfide
                                             with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens
                                             IGKV1-NL1*01 (83.20%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens
                                             IGKC*01 (108'-214')]; conjugated via a linker of the maleimide group
                                             (thioether bond with cysteinyl h 11 (227)) to two linear chains of
                                             methoxy polyethylene glycol 20 (mPEG20).




                                                                                                                                        389
Recommended INN: List 72                                    WHO Drug Information, Vol. 28, No. 3, 2014


 dapirolizumab pégol       immunoglobuline Fab' G1-kappa pégylé, anti-[Homo sapiens
                           CD40LG (CD40 ligand, CD40L, membre 5 de la superfamille des
                           ligands facteurs de nécrose tumorale, TNFSF5, protéine d'activation
                           apparentée au facteur de nécrose tumorale, TRAP, CD154)],
                           anticorps monoclonal humanisé pégylé;
                           fragment VH-(CH1-charnière) de la chaîne lourde gamma1 (1-229)
                           [VH humanisé (Homo sapiens IGHV3-74*01 (76.50%) -(IGHD)-
                           IGHJ1*01) [8.7.12] (1-118) -Homo sapiens IGHG1*01 (CH1 (119-
                           216), charnière 1-11 (217-227)) (119-227) -dialanyl (228-229)], (221-
                           214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA
                           humanisé (Homo sapiens IGKV1-NL1*01 (83.20%) -IGKJ1*01)
                           [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; conjugué via
                           un linker du groupe maléimide (liaison thioéther avec cystéinyl h 11
                           (227)) à deux chaînes linéaires de méthoxy polyéthylène glycol 20
                           (mPEG20).

 dapirolizumab pegol       inmunoglobulina Fab' G1-kappa pegilada, anti-[Homo sapiens
                           CD40LG (ligando CD40, CD40L, miembro 5 de la superfamilia de
                           ligandos factores de necrosis tumoral, TNFSF5, proteína de
                           activación relacionada con el factor de necrosis tumoral, TRAP,
                           CD154)], anticuerpo monoclonal humanizado pegilado;
                           fragmento VH-(CH1-bisagra) de la cadena pesada gamma1 (1-229)
                           [VH humanizado (Homo sapiens IGHV3-74*01 (76.50%) -(IGHD)-
                           IGHJ1*01) [8.7.12] (1-118) -Homo sapiens IGHG1*01 (CH1 (119-
                           216),bisagra 1-11 (217-227)) (119-227) -dialanil (228-229)], (221-
                           214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA
                           humanizado (Homo sapiens IGKV1-NL1*01 (83.20%) -IGKJ1*01)
                           [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; conjugado
                           mediante un conector del grupo maleimida (enlace tioéter con
                           cisteinil h 11 (227)) a dos cadenas lineales de metoxi polietilen glicol
                           20 (mPEG20)

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAVSGFSST                  NYHVHWVRQA       PGKGLEWMGV 50
                           IWGDGDTSYN SVLKSRFTIS RDTSKNTVYL                  QMNSLRAEDT       AVYYCARQLT 100
                           HYYVLAAWGQ GTLVTVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY 150
                           FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI 200
                           CNVNHKPSNT KVDKKVEPKS CDKTHTCAA                                               229

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCRASEDLY                  YNLAWYQRKP       GKAPKLLIYD 50
                           TYRLADGVPS RFSGSGSGTD YTLTISSLQP                  EDFASYYCQQ       YYKFPFTFGQ 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104)        22-95 145-201
                           Intra-L (C23-C104)        23'-88' 134'-194'
                           Inter-H-L (h 5-CL 126) 221-214'

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           None

                           Pegylation site / Site de pégylation / Posición de pegilación
                           C
                           227



 dasotralinum
 dasotraline               (1R,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-
                           1-amine

 dasotraline               (1R,4S)-4-(3,4-dichlorophényl)-1,2,3,4-tétrahydronaphthalén-
                           1-amine

 dasotralina               (1R,4S)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidronaftalen-1-amina




390
WHO Drug Information, Vol. 28, No. 3, 2014                                                   Recommended INN: List 72




                                             C16H15Cl2N

                                                   H         NH2




                                                         H



                                              Cl        Cl



 decernotinibum
 decernotinib                                (2R)-2-methyl-2-{[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-
                                             4-yl]amino}-N-(2,2,2-trifluoroethyl)butanamide

 décernotinib                                (2R)-2-méthyl-2-{[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-
                                             4-yl]amino}-N-(2,2,2-trifluoroéthyl)butanamide

 decernotinib                                (2R)-2-metil-2-{[2-(1H-pirrolo[2,3-b]piridin-3-il)pirimidin-4-il]amino}-
                                             N-(2,2,2-trifluoroetil)butanamida

                                             C18H19F3N6O

                                                   HN                        O
                                                                       H
                                              N                    N   N
                                                                                   N   CF3
                                                                                   H
                                                             N              CH 3
                                                                           CH3



 deldeprevirum
 deldeprevir                                 (2R,6R,12Z,13aS,14aR,16aS)-N-(cyclopropanesulfonyl)-
                                             6-[2-(3,3-difluoropiperidin-1-yl)-2-oxoethyl]-2-({7-methoxy-8-methyl-
                                             2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)-5,16-dioxo-
                                             1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-
                                             tetradecahydrocyclopropa[e]pyrrolo[1,2-
                                             a][1,4]diazacyclopentadecine-14a(5H)-carboxamide

 deldéprévir                                 (2R,6R,12Z,13aS,14aR,16aS)-N-(cyclopropanesulfonyl)-
                                             6-[2-(3,3-difluoropipéridin-1-yl)-2-oxoéthyl]-2-({7-méthoxy-8-méthyl-
                                             2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinoléin-4-yl}oxy)-5,16-dioxo-
                                             1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-
                                             tétradécahydrocyclopropa[e]pyrrolo[1,2-
                                             a][1,4]diazacyclopentadécine-14a(5H)-carboxamide

 deldeprevir                                 (2R,6R,12Z,13aS,14aR,16aS)-N-(ciclopropanosulfonil)-
                                             6-[2-(3,3-difluoropiperidin-1-il)-2-oxoetil]-2-({8-metil-7-metoxi-
                                             2-[4-(propan-2-il)-1,3-tiazol-2-il]quinolin-4-il}oxi)-5,16-dioxo-
                                             1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-
                                             tetradecahidrociclopropa[e]pirrolo[1,2-a][1,4]diazaciclopentadecina-
                                             14a(5H)-carboxamida




                                                                                                                        391
Recommended INN: List 72                                 WHO Drug Information, Vol. 28, No. 3, 2014




                           C45H56F2N6O8S2

                                       O
                                                             OCH3
                                   O       S
                                                                    CH3
                               O           NH
                                             O
                                                 H
                                                                    N
                                           N             H
                                           H                                N   CH3
                               H           O     N       O
                                                                        S       CH3
                                                 H O

                                                     N
                                                             F
                                                             F




 duligotuzumabum #
 duligotuzumab             immunoglobulin G1-kappa, anti-[Homo sapiens ERBB3 (receptor
                           tyrosine-protein kinase erbB-3, HER3)], humanized monoclonal
                           antibody;
                           gamma1 heavy chain (1-451) [humanized VH (Homo sapiens
                           IGHV3-74*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -
                           IGHG1*03 CH1 R120>K (218) (122-451)], (224-214')-disulfide with
                           kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens
                           IGKV1-39*01 (87.40%) -IGKJ2*01 L124>V (104)) [6.3.9] (1'-107') -
                           IGKC*01 (108'-214')]; dimer (230-230'':233-233'')-bisdisulfide

 duligotuzumab             immunoglobuline G1-kappa, anti-[Homo sapiens ERBB3 (récepteur
                           tyrosine-protéine kinase erbB3, HER3)], anticorps monoclonal
                           humanisé;
                           chaîne lourde gamma1 (1-451) [VH humanisé (Homo sapiens
                           IGHV3-74*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -
                           IGHG1*03 CH1 R120>K (218) (122-451)], (224-214')-disulfure avec
                           la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens
                           IGKV1-39*01 (87.40%) -IGKJ2*01 L124>V (104)) [6.3.9] (1'-107') -
                           IGKC*01 (108'-214')]; dimère (230-230'':233-233'')-bisdisulfure

 duligotuzumab             inmunoglobulina G1-kappa, anti-[Homo sapiens ERBB3 (receptor
                           tirosina-proteína kinasa erbB3, HER3)], anticuerpo monoclonal
                           humanizado;
                           cadena pesada gamma1 (1-451) [VH humanizado (Homo sapiens
                           IGHV3-74*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -
                           IGHG1*03 CH1 R120>K (218) (122-451)], (224-214')-disulfuro con la
                           cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens
                           IGKV1-39*01 (87.40%) -IGKJ2*01 L124>V (104)) [6.3.9] (1'-107') -
                           IGKC*01 (108'-214')]; dímero (230-230'':233-233'')-bisdisulfuro




392
WHO Drug Information, Vol. 28, No. 3, 2014                                                           Recommended INN: List 72




                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLVESGGG LVQPGGSLRL SCAASGFTLS                  GDWIHWVRQA       PGKGLEWVGE        50
                                             ISAAGGYTDY ADSVKGRFTI SADTSKNTAY                  LQMNSLRAED       TAVYYCARES       100
                                             RVSFEAAMDY WGQGTLVTVS SASTKGPSVF                  PLAPSSKSTS       GGTAALGCLV       150
                                             KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSSLGTQ       200
                                             TYICNVNHKP SNTKVDKKVE PKSCDKTHTC                  PPCPAPELLG       GPSVFLFPPK       250
                                             PKDTLMISRT PEVTCVVVDV SHEDPEVKFN                  WYVDGVEVHN       AKTKPREEQY       300
                                             NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                  ALPAPIEKTI       SKAKGQPREP       350
                                             QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD                  IAVEWESNGQ       PENNYKTTPP       400
                                             VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                  VMHEALHNHY       TQKSLSLSPG       450
                                             K                                                                                   451

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIQMTQSPSS LSASVGDRVT ITCRASQNIA                  TDVAWYQQKP       GKAPKLLIYS 50
                                             ASFLYSGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       SEPEPYTFGQ 100
                                             GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96        148-204       265-325  371-429
                                                      22''-96'' 148''-204'' 265''-325'' 371''-429''
                                             Intra-L 23'-88' 134'-194'
                                                      23'''-88''' 134'''-194'''
                                             Inter-H-L 224-214' 224''-214'''
                                             Inter-H-H 230-230'' 233-233''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             301, 301''




 duvelisibum
 duvelisib                                   8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-
                                             1(2H)-one

 duvélisib                                   8-chloro-2-phényl-3-[(1S)-1-(7H-purin-6-ylamino)éthyl]isoquinoléin-
                                             1(2H)-one

 duvelisib                                   8-cloro-2-fenil-3-[(1S)-1-(7H-purin-6-ilamino)etil]isoquinolein-
                                             1(2H)-ona

                                             C22H17ClN6O

                                                                           N
                                                               HN
                                                             H CH3              N

                                                                    N       N
                                                                    H
                                                            N

                                                Cl      O



 eftrenonacogum alfa #
 eftrenonacog alfa                           recombinant DNA derived human blood coagulation factor IX fusion
                                             protein with one Fc fragment of the human immunoglobulin G1 Fc
                                             fragment dimer, produced in HEK293H cells (glycoform alfa):
                                             human blood coagulation factor IX (EC 3.4.21.22, Christmas factor,
                                             plasma thromboplastin component) variant 148-T, fusion protein with
                                             human immunoglobulin G1 Fc fragment (IGHG1*01 H-CH2-CH3)-(6-
                                             231)-peptide (421-6':424-9')-bisdisulfide with human immunoglobulin
                                             G1 Fc fragment (IGHG1*01 H-CH2-CH3)-(6-231)-peptide




                                                                                                                                        393
Recommended INN: List 72                                            WHO Drug Information, Vol. 28, No. 3, 2014


 eftrénonacog alfa         protéine de fusion entre le facteur IX de coagulation sanguine
                           humain et l’un des fragments du dimère du fragment Fc de
                           l’immunoglobuline G1 humaine, produite par des cellules HEK293H
                           à partir d’ADN recombinant (glycoforme alfa) :
                           variant 148-T du facteur IX de coagulation humain (EC 3.4.21.22,
                           facteur Christmas, thromboplastine composant du plasma) protéine
                           de fusion avec le fragment Fc de l’immunoglobuline G1 humaine
                           (IGHG1*01 H-CH2-CH3)-(6-231)-peptide (421-6':424-9')-bisdisulfure
                           avec le fragment Fc de l’immunoglobuline G1 humaine (IGHG1*01
                           H-CH2-CH3)-(6-231)-peptide

 eftrenonacog alfa         proteína de fusión entre el factor IX de coagulación humano y uno
                           de los fragmentos del dímero del fragmento Fc de la
                           inmunoglobulina G1 humana, producida por células HEK293H a
                           partir de ADN recombinante (glicoforma alfa) :
                           variante 148-T del factor IX de coagulación humana (EC 3.4.21.22,
                           factor Christmas, tromboplastina componente del plasma) proteína
                           de fusión con el fragmento Fc de la inmunoglobulina G1
                           humana(IGHG1*01 H-CH2-CH3)-(6-231)-péptido (421-6':424-9')-
                           bisdisulfuro con el fragmento Fc de l’inmunoglobulina G1 humana
                           (IGHG1*01 H-CH2-CH3)-(6-231)-péptido


                           Fusion protein/ Protéine de fusion / Proteína de fusión
                           YNSGKLEEFV QGNLERECME EKCSFEEARE VFENTERTTE                        FWKQYVDGDQ       50
                           CESNPCLNGG SCKDDINSYE CWCPFGFEGK NCELDVTCNI                        KNGRCEQFCK       100
                           NSADNKVVCS CTEGYRLAEN QKSCEPAVPF PCGRVSVSQT                        SKLTRAETVF       150
                           PDVDYVNSTE AETILDNITQ STQSFNDFTR VVGGEDAKPG                        QFPWQVVLNG       200
                           KVDAFCGGSI VNEKWIVTAA HCVETGVKIT VVAGEHNIEE                        TEHTEQKRNV       250
                           IRIIPHHNYN AAINKYNHDI ALLELDEPLV LNSYVTPICI                        ADKEYTNIFL       300
                           KFGSGYVSGW GRVFHKGRSA LVLQYLRVPL VDRATCLRST                        KFTIYNNMFC       350
                           AGFHEGGRDS CQGDSGGPHV TEVEGTSFLT GIISWGEECA                        MKGKYGIYTK       400
                           VSRYVNWIKE KTKLTDKTHT CPPCPAPELL GGPSVFLFPP                        KPKDTLMISR       450
                           TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ                        YNSTYRVVSV       500
                           LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE                        PQVYTLPPSR       550
                           DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP                        PVLDSDGSFF       600
                           LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP                        G                641

                           Immunoglobulin Fc fragment / Fragment Fc de l'immunoglobuline / Fragmento Fc de la
                           inmunoglobulina
                           DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED 50'
                           PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK 100'
                           CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK 150'
                           GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG 200'
                           NVFSCSVMHE ALHNHYTQKS LSLSPG                                                226'

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           6'-421     9'-424    18-23       41'-101' 51-62       56-71      73-82     88-99     95-109
                           111-124 132-289 147'-205' 206-222 336-350 361-389 456-516 562-620

                           Modified residues / Résidus modifiés / Restos modificados
                                     E                                                              H NH2
                                                      HO2C H NH2                         D
                           7-8-15-17-20-21-26                                           64   HO2C
                             27-30-33-36-40                                                             CO2H
                              4-carboxyGlu        HO2C                CO2H         3-hydroxyAsp   H OH
                                  Y                                                                      H NH2
                                           HO       O                                      S
                                155              S                   H NH2             68-158    O    O
                                                                                   O-phosphonoSer   P        CO2H
                                               O O
                             O-sulfoTyr                                                          HO OH
                                                                          CO2H

                           Glycosylation sites (N, S, T) / Sites de glycosylation (N, S, T) / Posiciones de
                           glicosilación (N, S, T)
                           Ser-53* Ser-61* Asn-77' Asn-157 Thr-159* Asn-167 Thr-169* Asn-492
                           * partially modified / modifiés en partie / parcialmente modificados



 elbasvirum
 elbasvir                  dimethyl N,N'-([(6S)-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazine-
                           3,10-diyl]bis{1H-imidazole-5,2-diyl-(2S)-pyrrolidine-2,1-diyl[(2S)-3-
                           methyl-1-oxobutane-1,2-diyl]})biscarbamate

 elbasvir                  N,N'-([(6S)-6-phényl-6H-indolo[1,2-c][1,3]benzoxazine-
                           3,10-diyl]bis{1H-imidazole-5,2-diyl-(2S)-pyrrolidine-2,1-diyl[(2S)-3-
                           méthyl-1-oxobutane-1,2-diyl]})biscarbamate de diméthyle




394
WHO Drug Information, Vol. 28, No. 3, 2014                                                        Recommended INN: List 72


 elbasvir                                    N,N'-([(6S)-6-fenil-6H-indolo[1,2-c][1,3]benzoxazina-3,10-diil]bis{1H-
                                             imidazole-5,2-diil-(2S)-pirrolidina-2,1-diyl[(2S)-3-metil-1-oxobutano-
                                             1,2-diil]})biscarbamato de dimetilo
                                             C49H55N9O7
                                                                                                  H
                                                   CH3                                            N H
                                                            H
                                                            N           O
                                             H3C                            CH3                   N         N
                                                   H
                                                                    O                                 O         H CH3
                                                   N        O
                                                                                                  O
                                                            N                         N   O               NH      CH3
                                                   H                                              O
                                                       HN                             H
                                                                                                      CH3



 entasobulinum
 entasobulin                                 2-{1-[(4-chlorophenyl)methyl]-1H-indol-3-yl}-2-oxo-N-(quinolin-
                                             6-yl)acetamide

 entasobuline                                2-{1-[(4-chlorophényl)méthyl]-1H-indol-3-yl}-2-oxo-N-(quinoléin-
                                             6-yl)acétamide

 entasobulina                                2-{1-[(4-clorofenil)metil]-1H-indol-3-il}-2-oxo-N-(quinolein-
                                             6-il)acetamida

                                             C26H18ClN3O2
                                                                            O
                                                                                      H
                                                                                      N
                                                                N
                                                                                O
                                                                                              N


                                             Cl

 entospletinibum
 entospletinib                               6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-
                                             a]pyrazin-8-amine

 entosplétinib                               6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phényl]imidazo[1,2-
                                             a]pyrazin-8-amine

 entospletinib                               6-(1H-indazol-6-il)-N-[4-(morfolin-4-il)fenil]imidazo[1,2-a]pirazin-
                                             8-amina

                                             C23H21N7O

                                             O
                                                    N                   N         N

                                                                                              H
                                                                                              N
                                                                        N         N
                                                                        H                         N



 etiguanfacinum
 etiguanfacine                               ethyl N-{[2-(2,6-dichlorophenyl)acetyl]carbamimidoyl}carbamate

 étiguanfacine                               N-{[2-(2,6-dichlorophényl)acétyl]carbamimidoyl}carbamate d'éthyle

 etiguanfacina                               N-{[2-(2,6-diclorofenil)acetil]carbamimidoil}carbamato de etilo


                                                                                                                        395
Recommended INN: List 72                                                   WHO Drug Information, Vol. 28, No. 3, 2014




                           C12H13Cl2N3O3

                                          Cl
                                               O            NH        O

                                                    N             N         O         CH3
                                                    H             H
                                Cl



 ferricum derisomaltosum
 ferric derisomaltose      (1→6)-α-D-glucopyranan-(1→6)-D-glucitol iron(III) complex

 dérisomaltose ferrique    complexe de fer(III) et de (1→6)-α-D-glucopyranan-(1→6)-D-glucitol

 derisomaltosa férrica     complejo hierro(III) (1→6)-α-D-glucopiranan-(1→6)-D-glucitol
                                                                                       III
                           (C6H11O5)(C6H10O5)n(C6H13O5) Fe complex (n = 4.2)
                                CH2OH                        CH2                           CH2


                                     O                                O                          OH

                            OH                               OH                            OH         CH2OH
                                                                                                              FeIII complex
                           OH             O             OH                 O          OH

                                     OH                               OH        n                OH


                                                        n = 4.2



 fimaporfinum
 fimaporfin                4,4'-(15,20-diphenyl-7,8(or 12,13 or 17,18)-dihydro-21H,23H-
                           porphine-5,10-diyl)bisbenzenesulfonic acid, mixture of three isomers
                           A, B and C (25%,50%,25%)

 fimaporfine               acide 4,4'-(15,20-diphényl-7,8(ou 12,13 ou 17,18)-dihydro-21H,23H-
                           porphine-5,10-diyl)bisbenzènesulfonique, mélange de trois isomères
                           A, B et C (25%,50%,25%)

 fimaporfina               ácido 4,4'-(15,20-difenil-7,8(o 12,13 o 17,18)-dihidro-21H,23H-
                           porfirina-5,10-diil)bisbencenosulfónico, mezcla de tres isómeros A, B
                           y C (50%,25%,25%)

                           C44H32N4O6S2

                                                             SO3H                    A (7,8-dihydro)

                                                                                     B (12,13-dihydro)

                                                                                     C (17,18-dihydro)

                                                                           7
                                                                                8

                                               1        NH            N
                                                                                                       SO3H
                                                        N          HN
                                          18                                    12

                                                   17                      13




396
WHO Drug Information, Vol. 28, No. 3, 2014                                                              Recommended INN: List 72


 fletikumabum #
 fletikumab                                  immunoglobulin G4-kappa, anti-[Homo sapiens IL20 (interleukin 20,
                                             IL-20)], human monoclonal antibody;
                                             gamma4 heavy chain (1-454) [Homo sapiens VH (IGHV1-3*01
                                             (88.80%) -(IGHD)-IGHJ6*01) [8.8.20] (1-127) -IGHG4*01 (CH1 (128-
                                             225), hinge S10>P (235) (226-237), CH2 (238-347), CH3 (348-452),
                                             CHS (453-454)) (128-454)], (141-214')-disulfide with kappa light
                                             chain (1'-214') [Homo sapiens (V-KAPPA (IGKV1-13*02 (100.00%) -
                                             IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (233-
                                             233":236-236")-bisdisulfide

 flétikumab                                  immunoglobuline G4-kappa, anti-[Homo sapiens IL20 (interleukine
                                             20, IL-20)], anticorps monoclonal humain;
                                             chaîne lourde gamma4 (1-454) [Homo sapiens VH (IGHV1-3*01
                                             (88.80%) -(IGHD)-IGHJ6*01) [8.8.20] (1-127) -IGHG4*01 (CH1 (128-
                                             225), charnière S10>P (235) (226-237), CH2 (238-347), CH3 (348-
                                             452), CHS (453-454)) (128-454)], (141-214')-disulfure avec la chaîne
                                             légère kappa (1'-214') [Homo sapiens (V-KAPPA (IGKV1-13*02
                                             (100.00%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère
                                             (233-233":236-236")-bisdisulfure

 fletikumab                                  inmunoglobulina G4-kappa, anti-[Homo sapiens IL20 (interleukina
                                             20, IL-20)], anticuerpo monoclonal humano;
                                             cadena pesada gamma4 (1-454) [Homo sapiens VH (IGHV1-3*01
                                             (88.80%) -(IGHD)-IGHJ6*01) [8.8.20] (1-127) -IGHG4*01 (CH1 (128-
                                             225), bisagra S10>P (235) (226-237), CH2 (238-347), CH3 (348-
                                             452), CHS (453-454)) (128-454)], (141-214')-disulfuro con la cadena
                                             ligera kappa (1'-214') [Homo sapiens (V-KAPPA (IGKV1-13*02
                                             (100.00%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero
                                             (233-233":236-236")-bisdisulfuro
                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVQSGAE VKRPGASVKV SCKASGYTFT                  NDIIHWVRQA       PGQRLEWMGW        50
                                             INAGYGNTQY SQNFQDRVSI TRDTSASTAY                  MELISLRSED       TAVYYCAREP       100
                                             LWFGESSPHD YYGMDVWGQG TTVTVSSAST                  KGPSVFPLAP       CSRSTSESTA       150
                                             ALGCLVKDYF PEPVTVSWNS GALTSGVHTF                  PAVLQSSGLY       SLSSVVTVPS       200
                                             SSLGTKTYTC NVDHKPSNTK VDKRVESKYG                  PPCPPCPAPE       FLGGPSVFLF       250
                                             PPKPKDTLMI SRTPEVTCVV VDVSQEDPEV                  QFNWYVDGVE       VHNAKTKPRE       300
                                             EQFNSTYRVV SVLTVLHQDW LNGKEYKCKV                  SNKGLPSSIE       KTISKAKGQP       350
                                             REPQVYTLPP SQEEMTKNQV SLTCLVKGFY                  PSDIAVEWES       NGQPENNYKT       400
                                             TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF                  SCSVMHEALH       NHYTQKSLSL       450
                                             SLGK                                                                                454

                                             Light chain / Chaîne légère / Cadena ligera
                                             AIQLTQSPSS LSASVGDRVT ITCRASQGIS                  SALAWYQQKP       GKAPKLLIYD 50
                                             ASSLESGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       FNSYPLTFGG 100
                                             GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-96          154-210       268-328   374-432
                                                                   22''-96'' 154''-210'' 268''-328'' 374''-432''
                                             Intra-L (C23-C104) 23'-88'         134'-194'
                                                                   23'''-88''' 134'''-194'''
                                             Inter-H-L (CH1 10-CL 126) 141-214' 141''-214'''
                                             Inter-H-H (h 8, h 11)            233-233'' 236-236''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             304, 304''



 fosravuconazolum
 fosravuconazole                             {(1R,2R)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-
                                             1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propoxy}methyl
                                             dihydrogen phosphate

 fosravuconazole                             dihydrogénophosphate de {(1R,2R)-2-[4-(4-cyanophényl)-1,3-thiazol-
                                             2-yl]-1-(2,4-difluorophényl)-1-[(1H-1,2,4-triazol-
                                             1-yl)méthyl]propoxy}méthyle

                                                                                                                                           397
Recommended INN: List 72                                  WHO Drug Information, Vol. 28, No. 3, 2014




 fosravuconazol            dihidrógenofosfato de {(1R,2R)-2-[4-(4-cianofenil)-1,3-tiazol-2-il]-
                           1-(2,4-difluorofenil)-1-[(1H-1,2,4-triazol-1-il)metil]propoxi}metilo

                           C23H20F2N5O5PS

                                                                 F



                                                      F
                                                  S
                                                                 O
                                                                          O     OH
                           NC                 N
                                                                              P OH
                                                      H   CH3 N
                                                                     N       O

                                                             N

 gemilukastum
 gemilukast                4,4'-[4-fluoro-7-(2-{4-[4-(3-fluoro-
                           2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-
                           1,3-diyl]dibutanoic acid

 gémilukast                acide 4,4'-[4-fluoro-7-(2-{4-[4-(3-fluoro-
                           2-méthylphényl)butoxy]phényl}éthynyl)-2-méthyl-1H-indole-
                           1,3-diyl]dibutanoïque

 gemilukast                ácido 4,4'-[4-fluoro-7-(2-{4-[4-(3-fluoro-2-metilfenil)butoxi]fenil}etinil)-
                           2-metil-1H-indol-1,3-diil]dibutanoico

                           C36H37F2NO5
                                                                                      CH3
                                                                         O                  F




                                     F            N                  CO2H

                           HO2C                   CH3

 grapiprantum
 grapiprant                N-{2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-
                           1-yl)phenyl]ethyl}-N'-[(4-methylphenyl)sulfonyl]urea

 grapiprant                N-{2-[4-(2-éthyl-4,6-diméthyl-1H-imidazo[4,5-c]pyridin-
                           1-yl)phényl]éthyl}-N'-[(4-méthylphényl)sulfonyl]urée

 grapiprant                N-{2-[4-(2-etil-4,6-dimetil-1H-imidazo[4,5-c]piridin-1-il)fenil]etil}-
                           N'-[(4-metilfenil)sulfonil]urea

                           C26H29N5O3S
                                                                                     CH3
                              H3C                                H           H
                                                                 N           N
                                                                                 S
                                N                                             O O
                                                                      O
                                          N
                           H3C
                                      N         CH3




398
WHO Drug Information, Vol. 28, No. 3, 2014                                                   Recommended INN: List 72


 grazoprevirum
 grazoprevir                                 (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-
                                             [(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-
                                             3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-
                                             8H-7,10-
                                             methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,1
                                             -b]quinoxaline-8-carboxamide

 grazoprévir                                 (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-
                                             [(cyclopropylsulfonyl)carbamoyl]-2-éthénylcyclopropyl}-14-méthoxy-
                                             3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tétradécahydro-
                                             8H-7,10-
                                             méthanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadécino[11,1
                                             2-b]quinoxaline-8-carboxamide

 grazoprevir                                 (1aR,5S,8S,10R,22aR)-5-terc-butil-N-{(1R,2S)-1-
                                             [(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}-14-metoxi-3,6-
                                             dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahidro-8H-7,10-
                                             metanociclopropa[18,19][1,10,3,6]dioxadiazaciclononadecino[11,12-
                                             b]quinoxalina-8-carboxamida

                                             C38H50N6O9S

                                               H
                                                                        N


                                                   O            O       N             OCH3
                                               H                    H
                                               O       NH
                                                   H                            O    O O
                                             H3C            N           H
                                                                        N             S
                                                                                    N
                                              H3C CH3 O         H                   H
                                                                    O
                                                                            H       CH2



 icosabutas
 icosabutate                                 rac-2-[(5Z,8Z,11Z,14Z,17Z)icosa-5,8,11,14,17-pentaen-
                                             1-yloxy]butanoic acid

 icosabutate                                 acide rac-2-[(5Z,8Z,11Z,14Z,17Z)icosa-5,8,11,14,17-pentaén-
                                             1-yloxy]butanoïque

 icosabutato                                 ácido rac-2-[(5Z,8Z,11Z,14Z,17Z)icosa-5,8,11,14,17-pentaen-
                                             1-iloxi]butanoico

                                             C24H38O3

                                                   CH3                                                H   CO2H
                                                                                                             CH3
                                                                                                     O
                                                                            and enantiomer
                                                                            et énantiomère
                                                                            y enantiómero



 idalopirdinum
 idalopirdine                                2-(6-fluoro-1H-indol-3-yl)-N-{[3-(2,2,3,3-
                                             tetrafluoropropoxy)phenyl]methyl}ethanamine

 idalopirdine                                2-(6-fluoro-1H-indol-3-yl)-N-{[3-(2,2,3,3-
                                             tétrafluoropropoxy)phényl]méthyl}éthanamine

                                                                                                                   399
Recommended INN: List 72                                 WHO Drug Information, Vol. 28, No. 3, 2014




 idalopirdine              2-(6-fluoro-1H-indol-3-yl)-N-{[3-(2,2,3,3-
                           tétrafluoropropoxy)phényl]méthyl}éthanamine

 idalopirdina              2-(6-fluoro-1H-indol-3-il)-N-{[3-(2,2,3,3-
                           tetrafluoropropoxi)fenil]metil}etanamina

                           C20H19F5N2O

                                    HN
                                                                              F   F
                                                                          O               F
                                                    N
                           F                        H
                                                                                      F



 lefamulinum
 lefamulin                 (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyl-5-hydroxy-4,6,9,10-
                           tetramethyl-1-oxodecahydro-3a,9-propanocyclopenta[8]annulen-8-yl
                           {[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]sulfanyl}acetate

 léfamuline                {[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]sulfanyl}acétate de
                           (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-éthényl-5-hydroxy-4,6,9,10-
                           tétraméthyl-1-oxodécahydro-3a,9-propano-
                           3aH-cyclopenta[8]annulén-8-yle

 lefamulina                {[(1R,2R,4R)-4-amino-2-hidroxiciclohexil]sulfanil}acetato de
                           (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-etenil-5-hidroxi-4,6,9,10-
                           tetrametil-1-oxodecahidro-3a,9-propanociclopenta[8]anulen-8-ilo

                           C28H45NO5S

                                                                    H
                                                                        CH3
                               H           H                H H3C
                                                        O                 O
                           H2 N            S
                                          OH        O          H
                                      H
                                                H3 C
                                               H2 C
                                                        HO H        CH3
                                                               H



 lerimazolinum
 lerimazoline              2-[(2,4,6-trimethylphenyl)methyl]-4,5-dihydro-1H-imidazole

 lérimazoline              2-[(2,4,6-triméthylphényl)méthyl]-4,5-dihydro-1H-imidazole

 lerimazolina              2-[(2,4,6-trimetilfenil)metil]-4,5-dihidro-1H-imidazol

                           C13H18N2

                           H3C            CH3
                                                N

                                                    N
                                                    H
                                    CH3




400
WHO Drug Information, Vol. 28, No. 3, 2014                                                  Recommended INN: List 72




 lifastuzumabum vedotinum #
 lifastuzumab vedotin                        immunoglobulin G1-kappa auristatin E conjugate, anti-[Homo
                                             sapiens SLC34A2 (solute carrier family 34 sodium phosphate
                                             member 2, sodium/phosphate cotransporter 2B, NaPi2b, NaPi3b)],
                                             humanized monoclonal antibody conjugated to auristatin E;
                                             gamma1 heavy chain (1-450) [humanized VH (Homo sapiens
                                             IGHV3-23*04 (85.70%) -(IGHD)-IGHJ5*01) [8.8.13] (1-120) -Homo
                                             sapiens IGHG1*03 (CH1 R120>K (217) (121-218), hinge (219-233),
                                             CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-
                                             219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA
                                             (Homo sapiens IGKV1-39*01 (78.00%) -IGKJ1*01) [11.3.9] (1'-112')
                                             -Homo sapiens IGKC*01 (113'-219')]; dimer (229-229":232-232")-
                                             bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to
                                             monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-
                                             valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type
                                             linker
                                             For the vedotin part, please refer to the document "INN for pharmaceutical
                                             substances: Names for radicals, groups and others"*.

 lifastuzumab védotine                       immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[Homo
                                             sapiens SLC34A2 (membre 2 de la famille 34 sodium phosphate de
                                             transporteurs de solutés, cotransporteur 2B de sodium/phosphate,
                                             NaPi2b, NaPi3b)], anticorps monoclonal humanisé conjugué à
                                             l'auristatine E;
                                             chaîne lourde gamma1 (1-450) [VH humanisé (Homo sapiens
                                             IGHV3-23*04 (85.70%) -(IGHD)-IGHJ5*01) [8.8.13] (1-120) -Homo
                                             sapiens IGHG1*03 (CH1 R120>K (217) (121-218), charnière (219-
                                             233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)],
                                             (223-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA
                                             humanisé (Homo sapiens IGKV1-39*01 (78.00%) -IGKJ1*01)
                                             [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (229-
                                             229":232-232")-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en
                                             moyenne, au monométhylauristatine E (MMAE), via un linker clivable
                                             de type maléimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl
                                             (mc-val-cit-PABC)
                                             Pour la partie védotine, veuillez-vous référer au document "INN for
                                             pharmaceutical substances: Names for radicals, groups and others"*.

 lifastuzumab vedotina                       inmunoglobulina G1-kappa conjugada con la auristatina E, anti-
                                             [Homo sapiens SLC34A2 (miembro 2 de la familia 34 sodio fosfato
                                             de transportadores de solutos, cotransportador 2B de sodio/fosfato,
                                             NaPi2b, NaPi3b)], anticuerpo monoclonal humanizado conjugado
                                             con auristatina E;
                                             cadena pesada gamma1 (1-450) [VH humanizada (Homo sapiens
                                             IGHV3-23*04 (85.70%) -(IGHD)-IGHJ5*01) [8.8.13] (1-120) -Homo
                                             sapiens IGHG1*03 (CH1 R120>K (217) (121-218), bisagra (219-
                                             233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)],
                                             (223-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA
                                             humanizado (Homo sapiens IGKV1-39*01 (78.00%) -IGKJ1*01)
                                             [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (229-
                                             229":232-232")-bisdisulfuro; conjugado, en una media de 3 a 4
                                             restos cisteinil, con monometilauristatina E (MMAE), mediante un
                                             conector separable de tipo maleimidocaproil-valil-citrulinil-
                                             p-aminobenciloxicarbonilo (mc-val-cit-PABC)
                                             Para la fracción vedotina pueden referirse al documento "INN for
                                             pharmaceutical substances: Names for radicals, groups and others"*.




                                                                                                                          401
Recommended INN: List 72                                           WHO Drug Information, Vol. 28, No. 3, 2014




                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAASGFSFS                  DFAMSWVRQA       PGKGLEWVAT        50
                           IGRVAFHTYY PDSMKGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYYCARHR       100
                           GFDVGHFDFW GQGTLVTVSS ASTKGPSVFP                  LAPSSKSTSG       GTAALGCLVK       150
                           DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSSLGTQT       200
                           YICNVNHKPS NTKVDKKVEP KSCDKTHTCP                  PCPAPELLGG       PSVFLFPPKP       250
                           KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                  YVDGVEVHNA       KTKPREEQYN       300
                           STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                  LPAPIEKTIS       KAKGQPREPQ       350
                           VYTLPPSREE MTKNQVSLTC LVKGFYPSDI                  AVEWESNGQP       ENNYKTTPPV       400
                           LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                  MHEALHNHYT       QKSLSLSPGK       450

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCRSSETLV                  HSSGNTYLEW       YQQKPGKAPK 50
                           LLIYRVSNRF SGVPSRFSGS GSGTDFTLTI                  SSLQPEDFAT       YYCFQGSFNP 100
                           LTFGQGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                           VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                           VTHQGLSSPV TKSFNRGEC                                                          219

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          147-203       264-324 370-428
                                                 22''-96'' 147''-203'' 264''-324'' 370''-428''
                           Intra-L (C23-C104) 23'-93'        139'-199'
                                                 23'''-93''' 139'''-199'''
                           Inter-H-L (h 5-CL 126) * 223-219' 223''-219'''
                           Inter-H-H (h 11, h 14) * 229-229'' 232-232''
                           *Two or three of the inter-chain disulfide bridges are not present, an average of 3 to 4
                            cysteinyl being conjugated each via a thioether bond to a drug linker.
                           *Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 3 à 4 cystéinyl
                            en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.
                           *Faltan dos o tres puentes disulfuro inter-catenarios, una media de 3 a 4 cisteinil está
                           conjugada a conectores de principio activo.

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           300, 300''



 lotilanerum
 lotilaner                 3-methyl-N-{2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl}-5-[(5S)-
                           5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-
                           3-yl]thiophene-2-carboxamide

 lotilaner                 3-méthyl-N-{2-oxo-2-[(2,2,2-trifluoroéthyl)amino]éthyl}-5-[(5S)-5-
                           (3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydro-1,2-oxazol-
                           3-yl]thiophène-2-carboxamide

 lotilaner                 3-metil-N-{2-oxo-2-[(2,2,2-trifluoroetil)amino]etil}-5-[(5S)-5-(3,4,5-
                           triclorofenil)-5-(trifluorometil)-4,5-dihidro-1,2-oxazol-3-il]tiofeno-
                           2-carboxamida

                           C20H14Cl3F6N3O3S

                                        F3C        O
                                                         N                 O
                           Cl                                                                 H
                                                                  S                           N         CF3
                                                                                N
                                                                                H
                           Cl                                                            O
                                      Cl                                CH3


 lubabegronum
 lubabegron                2-{4-[2-({(2S)-2-hydroxy-3-[2-(thiophen-2-yl)phenoxy]propyl}amino)-
                           2-methylpropyl]phenoxy}pyridine-3-carbonitrile

 lubabégron                2-{4-[2-({(2S)-2-hydroxy-3-[2-(thiophén-2-yl)phénoxy]propyl}amino)-
                           2-méthylpropyl]phénoxy}pyridine-3-carbonitrile

 lubabegrón                2-{4-[2-({(2S)-2-hidroxi-3-[2-(tiofen-2-il)fenoxi]propil}amino)-
                           2-metilpropil]fenoxi}piridina-3-carbonitrilo




402
WHO Drug Information, Vol. 28, No. 3, 2014                                                              Recommended INN: List 72




                                             C29H29N3O3S
                                                                                                           CN
                                                                                                  O
                                                                        H3C     CH3
                                                                                                       N
                                                         O               N
                                                                         H
                                                               H OH
                                             S




 luspaterceptum #
 luspatercept                                fusion protein for immune applications (FPIA) comprising the Homo
                                             sapiens ACVR2B (activin receptor type 2B, activin A receptor type
                                             IIB, activin receptor type IIB, ACTR-IIB, ActR-IIB) extracellular
                                             domain, fused with Homo sapiens immunoglobulin G1 Fc fragment;
                                             Homo sapiens ACVR2B precursor fragment 25-131 L79>D (55) (1-
                                             107) -linker triglycyl (108-110) -gamma1 chain H-CH2-CH3 fragment
                                             [Homo sapiens IGHG1*03 (hinge 8-15 (111-118), CH2 (119-228),
                                             CH3 (229-333), CHS (334-335))] (111-335); dimer (114-114':117-
                                             117')-bisdisulfide

 luspatercept                                protéine de fusion pour applications immunitaires (FPIA) comprenant
                                             le domaine extracellulaire d'Homo sapiens ACVR2B (récepteur de
                                             type 2B de l'activine, récepteur de type IIB de l'activine A, récepteur
                                             de type IIB de l'activine, ACTR-IIB, ActR-IIB), fusionné au fragment
                                             Fc de l'Homo sapiens immunoglobuline G1;
                                             Homo sapiens ACVR2B fragment 25-131 du précurseur L79>D (55)
                                             (1-107) -linker triglycyl (108-110) -fragment H-CH2-CH3 de la chaîne
                                             gamma1 [Homo sapiens IGHG1*03 (charnière 8-15 (111-118), CH2
                                             (119-228), CH3 (229-333), CHS (334-335))] (111-335); dimère (114-
                                             114':117-117')-bisdisulfure

 luspatercept                                proteína de fusión para aplicaciones inmunitarias (FPIA) que
                                             comprende el dominio extracelular d'Homo sapiens ACVR2B
                                             (receptor de tipo 2B de la activina, receptor de tipo IIB de la activina
                                             A, receptor de tipo IIB de la activina, ACTR-IIB, ActR-IIB), fusionada
                                             con el fragmento Fc de la inmunoglobulina G1 de Homo sapiens ;
                                             Homo sapiens ACVR2B fragmento 25-131 del precursor L79>D (55)
                                             (1-107) -linker triglicil (108-110) -fragmento H-CH2-CH3 de la
                                             cadena gamma1 [Homo sapiens IGHG1*03 (bisagra 8-15 (111-118),
                                             CH2 (119-228), CH3 (229-333), CHS (334-335))] (111-335); dímero
                                             (114-114':117-117')-bisdisulfuro
                                             Fused chain / chaine fusionnée / cadena fusionada
                                             ETRECIYYNA NWELERTNQS GLERCEGEQD KRLHCYASWR                        NSSGTIELVK        50
                                             KGCWDDDFNC YDRQECVATE ENPQVYFCCC EGNFCNERFT                        HLPEAGGPEV       100
                                             TYEPPPTGGG THTCPPCPAP ELLGGPSVFL FPPKPKDTLM                        ISRTPEVTCV       150
                                             VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV                        VSVLTVLHQD       200
                                             WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP                        PSREEMTKNQ       250
                                             VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG                        SFFLYSKLTV       300
                                             DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK                                              335

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intrachain ACVR2B                   5-35 25-53 60-79 66-78 80-85
                                                                                 5'-35' 25'-53' 60'-79' 66'-78' 80'-85'
                                                          IGHG1 (C23-C104) 149-209 255-313
                                                                                 149'-209' 255'-313'
                                             Interchain IGHG1 (h 11, h 14) 114-114' 117-117'

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             ACVR2B:
                                             18, 41, 18', 41'
                                             IGHG1 CH2 N84.4:
                                             185, 185'




                                                                                                                                               403
Recommended INN: List 72                                       WHO Drug Information, Vol. 28, No. 3, 2014




 mipsagarginum
                                                                                    2+
 mipsagargin               sarcoplasmic/endoplasmic reticulum Ca dependent ATPase
                           (SERCA) inhibitor conjugated to a peptide targeting prostate-specific
                           membrane antigen (PSMA):
                             4
                           N -(12-{[(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acetyloxy)-
                           3,3a-dihydroxy-3,6,9-trimethyl-8-{[(2Z)-2-methylbut-2-enoyl]oxy}-
                           7-(octanoyloxy)-2-oxo-2,3,3a,4,5,6,6a,7,8,9b-decahydroazuleno[4,5-
                           b]furan-4-yl]oxy}-12-oxododecyl)-L-asparaginyl-L-γ-glutamyl-
                           L-γ-glutamyl-L-γ-glutamyl-L-glutamic acid

                                                                                     2+
 mipsagargine              inhibiteur de l'ATPase dépendante du Ca du réticulum
                           sarcoplasmique/endoplasmique conjugué à un peptide ciblant
                           l'antigène prostatique membranaire spécifique (APMS):
                                   4
                           acide N -(12-{[(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acétyloxy)-
                           3,3a-dihydroxy-3,6,9-triméthyl-8-{[(2Z)-2-méthylbut-2-énoyl]oxy}-
                           7-(octanoyloxy)-2-oxo-2,3,3a,4,5,6,6a,7,8,9b-décahydroazuléno[4,5-
                           b]furan-4-yl]oxy}-12-oxododécyl)-L-asparaginyl-L-γ-glutamyl-
                           L-γ-glutamyl-L-γ-glutamyl-L-glutamique

                                                                                         2+
 mipsagargina              inhibidor de la ATPasa dependiente de Ca de retículo
                           endoplásmico/sarcoplásmico (SERCA) conjugado con un péptido
                           cuya diana es el antígeno de membrana especifico de la próstata
                           (PSMA):
                                   4
                           ácido N -(12-{[(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acetiloxi)-
                           3,3a-dihidroxi-3,6,9-trimetil-8-{[(2Z)-2-metilbut-2-enoil]oxi}-
                           7-(octanoiloxi)-2-oxo-2,3,3a,4,5,6,6a,7,8,9b-decahidroazuleno[4,5-
                           b]furan-4-il]oxi}-12-oxododecil)-L-asparaginil-L-γ-glutamil-
                           L-γ-glutamil-L-γ-glutamil-L-glutámico

                           C66H100N6O27

                                                            O
                           H3C         O       CH3     O         OH
                                           H     H
                                                                CH3
                                       O                       OH
                                 CH3                   H
                                           O                     O
                                             H O           H
                                                 CH3                 O
                                             O
                                             O   CH3
                                           CH3

                                                           O
                                               H                     H   CO2H
                                               N                                     OH
                                                                 N
                                                       H   NH2   H
                                                   O                            O    4




 modotuximabum #
 modotuximab               immunoglobulin G1-kappa, anti-[Homo sapiens EGFR (epidermal
                           growth factor receptor, ERBB1, HER1) domain III], chimeric
                           monoclonal antibody;
                           gamma1 heavy chain (1-448) [Mus musculus VH (IGHV1S81*02 -
                           (IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*03 CHS
                           K2>del (120-448)], (222-219')-disulfide with kappa light chain (1'-
                           219') [Mus musculus V-KAPPA (IGKV2-109*01 -IGKJ2*01) [11.3.9]
                           (1'-112') -Homo sapiens IGKC*01 (113'-219')]; (228-228'':231-231'')-
                           bisdisulfide dimer




404
WHO Drug Information, Vol. 28, No. 3, 2014                                                            Recommended INN: List 72


 modotuximab                                 immunoglobuline G1-kappa, anti-[Homo sapiens EGFR (récepteur
                                             du facteur de croissance épidermique ERBB1, HER1) domaine III],
                                             anticorps monoclonal chimérique;
                                             chaîne lourde gamma1 (1-448) [Mus musculus VH (IGHV1S81*02 -
                                             (IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*03 CHS
                                             K2>del (120-448)], (222-219')-disulfure avec la chaîne légère kappa
                                             (1'-219') [Mus musculus V-KAPPA (IGKV2-109*01 -IGKJ2*01)
                                             [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (228-
                                             228'':231-231'')-bisdisulfure

 modotuximab                                 inmunoglobulina G1-kappa, anti-[EGFR de Homo sapiens (receptor
                                             del factor de crecimiento epidérmico ERBB1, HER1) dominio III],
                                             anticuerpo monoclonal quimérico;
                                             cadena ligera gamma1 (1-448) [Mus musculus VH (IGHV1S81*02 -
                                             (IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*03 CHS
                                             K2>del (120-448)], (222-219')-disulfuro con la cadena ligera kappa
                                             (1'-219') [Mus musculus V-KAPPA (IGKV2-109*01 -IGKJ2*01)
                                             [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (228-
                                             228'':231-231'')-bisdisulfuro

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLQQPGAE LVEPGGSVKL SCKASGYTFT                  SHWMHWVKQR       PGQGLEWIGE        50
                                             INPSSGRNNY NEKFKSKATL TVDKSSSTAY                  MQFSSLTSED       SAVYYCVRYY       100
                                             GYDEAMDYWG QGTSVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                                             YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                                             ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                                             DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                                             TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                                             YTLPPSREEM TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                                             DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPG         448

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIVMTQAAFS NPVTLGTSAS ISCRSSKSLL                  HSNGITYLYW       YLQKPGQSPQ 50
                                             LLIYQMSNLA SGVPDRFSSS GSGTDFTLRI                  SRVEAEDVGV       YYCAQNLELP 100
                                             YTFGGGTKLE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                                             VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                                             VTHQGLSSPV TKSFNRGEC                                                          219

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96 146-202              263-323 369-427
                                                      22''-96'' 146''-202'' 263''-323'' 369''-427''
                                             Intra-L 23'-93' 139'-199'
                                                      23'''-93''' 139'''-199'''
                                             Inter-H-L 222-219' 222''-219'''
                                             Inter-H-H 228-228'' 231-231''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             299, 299''




 osilodrostatum
 osilodrostat                                4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-
                                             3-fluorobenzonitrile

 osilodrostat                                4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-
                                             3-fluorobenzonitrile

 osilodrostat                                4-[(5R)-6,7-dihidro-5H-pirrolo[1,2-c]imidazol-5-il]-3-fluorobenzonitrilo

                                             C13H10FN3

                                               N

                                                   N
                                                           H



                                                       F              CN



                                                                                                                                         405
Recommended INN: List 72                                    WHO Drug Information, Vol. 28, No. 3, 2014




 otlertuzumabum #
 otlertuzumab              immunoglobulin G1-kappa heavy chain dimer, anti-[Homo sapiens
                           CD37 (tetraspanin-26, TSPAN26)], humanized monoclonal antibody;
                           gamma1-kappa heavy chain ‘VH-linker-V-KAPPA-hinge-CH2-CH3'
                           (1-483) [humanized VH (Homo sapiens IGHV5-51*01 (84.70%) -
                           (IGHD)-IGHJ5*01) [8.8.9] (1-116) -linker pentakis(tetraglycyl-seryl)
                           (117-141) -humanized V-KAPPA (Homo sapiens IGKV3-NL2
                           (89.90%) -IGKJ1*01) [6.3.9] (142-248) -linker glycyl-aspartyl-
                           glutaminyl (249-251) -Homo sapiens IGHG1*01 (hinge C5>S (256),
                           C11>S (262) (252-266), CH2 (267-376), CH3 (377-481), CHS (482-
                           483)) (252-483)]; dimer (265-265')-disulfide

 otlertuzumab              immunoglobuline G1-kappa chaîne lourde dimère, anti-[Homo
                           sapiens CD37 (tétraspanine-26, TSPAN26)], anticorps monoclonal
                           humanisé;
                           gamma1-kappa chaîne lourde ‘VH-linker-V-KAPPA-charnière-CH2-
                           CH3' (1-483) [VH humanisé (Homo sapiens IGHV5-51*01 (84.70%) -
                           (IGHD)-IGHJ5*01) [8.8.9] (1-116) -linker pentakis(tétraglycyl-séryl)
                           (117-141) -V-KAPPA humanisé (Homo sapiens IGKV3-NL2
                           (89.90%) -IGKJ1*01) [6.3.9] (142-248) -linker glycyl-aspartyl-
                           glutaminyl (249-251) -Homo sapiens IGHG1*01 (charnière C5>S
                           (256), C11>S (262) (252-266), CH2 (267-376), CH3 (377-481), CHS
                           (482-483)) (252-483)]; dimère (265-265')-disulfure

 otlertuzumab              inmunoglobulina G1-kappa cadena pesada dímero, anti-[Homo
                           sapiens CD37 (tetraspanina-26, TSPAN26)], anticuerpo monoclonal
                           humanizado;
                           gamma1-kappa cadena pesada ‘VH-linker-V-KAPPA-bisagra-CH2-
                           CH3' (1-483) [VH humanizado (Homo sapiens IGHV5-51*01
                           (84.70%) -(IGHD)-IGHJ5*01) [8.8.9] (1-116) -linker
                           pentakis(tetraglicil-seril) (117-141) -V-KAPPA humanizado (Homo
                           sapiens IGKV3-NL2 (89.90%) -IGKJ1*01) [6.3.9] (142-248) -linker
                           glicil-aspartil-glutaminil (249-251) -Homo sapiens IGHG1*01
                           (bisagraC5>S (256), C11>S (262) (252-266), CH2 (267-376), CH3
                           (377-481), CHS (482-483)) (252-483)]; dímero (265-265')-disulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVQSGAE VKKPGESLKI SCKGSGYSFT                  GYNMNWVRQM       PGKGLEWMGN        50
                           IDPYYGGTTY NRKFKGQVTI SADKSISTAY                  LQWSSLKASD       TAMYYCARSV       100
                           GPFDSWGQGT LVTVSSGGGG SGGGGSGGGG                  SGGGGSGGGG       SEIVLTQSPA       150
                           TLSLSPGERA TLSCRASENV YSYLAWYQQK                  PGQAPRLLIY       FAKTLAEGIP       200
                           ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ                  HHSDNPWTFG       QGTKVEIKGD       250
                           QEPKSSDKTH TSPPCPAPEL LGGPSVFLFP                  PKPKDTLMIS       RTPEVTCVVV       300
                           DVSHEDPEVK FNWYVDGVEV HNAKTKPREE                  QYNSTYRVVS       VLTVLHQDWL       350
                           NGKEYKCKVS NKALPAPIEK TISKAKGQPR                  EPQVYTLPPS       RDELTKNQVS       400
                           LTCLVKGFYP SDIAVEWESN GQPENNYKTT                  PPVLDSDGSF       FLYSKLTVDK       450
                           SRWQQGNVFS CSVMHEALHN HYTQKSLSLS                  PGK                               483

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96        164-229      297-357 403-461
                                                 22''-96'' 164''-229'' 297''-357'' 403''-461''
                           Inter-H-H (h 14)      265-265'

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           333, 333''




406
WHO Drug Information, Vol. 28, No. 3, 2014                                                                     Recommended INN: List 72


 pembrolizumabum #
 pembrolizumab                               immunoglobulin G4-kappa, anti-[Homo sapiens PDCD1
                                             (programmed cell death 1, PD-1, PD1, CD279)], humanized
                                             monoclonal antibody;
                                             gamma4 heavy chain (1-447) [humanized VH (Homo sapiens
                                             IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01 L123>T (115)) [8.8.13] (1-
                                             120) -Homo sapiens IGHG4*01 (CH1 (121-218), hinge S10>P (228)
                                             (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (121-
                                             447)], (134-218')-disulfide with kappa light chain (1'-218') [humanized
                                             V-KAPPA (Homo sapiens IGKV3D-11*01 (85.10%) -IGKJ4*01)
                                             [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')]; dimer (226-
                                             226":229-229")-bisdisulfide

 pembrolizumab                               immunoglobuline G4-kappa, anti-[Homo sapiens PDCD1 (protéine 1
                                             de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps
                                             monoclonal humanisé;
                                             chaîne lourde gamma4 (1-447) [VH humanisé (Homo sapiens
                                             IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01 L123>T (115)) [8.8.13]
                                             (1-120) -Homo sapiens IGHG4*01 (CH1 (121-218), charnière S10>P
                                             (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447))
                                             (121-447)], (134-218')-disulfure avec la chaîne légère kappa (1'-218')
                                             [V-KAPPA humanisé (Homo sapiens IGKV3D-11*01 (85.10%) -
                                             IGKJ4*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')];
                                             dimère (226-226":229-229")-bisdisulfure

 pembrolizumab                               inmunoglobulina G4-kappa, anti-[PDCD1 de Homo sapiens (proteína
                                             1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo
                                             monoclonal humanizado;
                                             cadena pesada gamma4 (1-447) [VH humanizado (Homo sapiens
                                             IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01 L123>T (115)) [8.8.13]
                                             (1-120) -Homo sapiens IGHG4*01 (CH1 (121-218), bisagra S10>P
                                             (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447))
                                             (121-447)], (134-218')-disulfuro con la cadena ligera kappa (1'-218')
                                             [V-KAPPA humanizado (Homo sapiens IGKV3D-11*01 (85.10%) -
                                             IGKJ4*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')];
                                             dímero (226-226":229-229")-bisdisulfuro


                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVQSGVE VKKPGASVKV SCKASGYTFT                  NYYMYWVRQA       PGQGLEWMGG        50
                                             INPSNGGTNF NEKFKNRVTL TTDSSTTTAY                  MELKSLQFDD       TAVYYCARRD       100
                                             YRFDMGFDYW GQGTTVTVSS ASTKGPSVFP                  LAPCSRSTSE       STAALGCLVK       150
                                             DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSSLGTKT       200
                                             YTCNVDHKPS NTKVDKRVES KYGPPCPPCP                  APEFLGGPSV       FLFPPKPKDT       250
                                             LMISRTPEVT CVVVDVSQED PEVQFNWYVD                  GVEVHNAKTK       PREEQFNSTY       300
                                             RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS                  SIEKTISKAK       GQPREPQVYT       350
                                             LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPVLDS       400
                                             DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE                  ALHNHYTQKS       LSLSLGK          447

                                             Light chain / Chaîne légère / Cadena ligera
                                             EIVLTQSPAT LSLSPGERAT LSCRASKGVS                  TSGYSYLHWY       QQKPGQAPRL 50
                                             LIYLASYLES GVPARFSGSG SGTDFTLTIS                  SLEPEDFAVY       YCQHSRDLPL 100
                                             TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK                  SGTASVVCLL       NNFYPREAKV 150
                                             QWKVDNALQS GNSQESVTEQ DSKDSTYSLS                  STLTLSKADY       EKHKVYACEV 200
                                             THQGLSSPVT KSFNRGEC                                                           218

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-96          147-203       261-321   367-425
                                                                   22''-96'' 147''-203'' 261''-321'' 367''-425''
                                             Intra-L (C23-C104) 23'-92'         138'-198'
                                                                   23'''-92''' 138'''-198'''
                                             Inter-H-L (CH1 10-CL 126) 134-218' 134''-218'''
                                             Inter-H-H (h 8, h 11)            226-226'' 229-229''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             297, 297''


 pexmetinibum
 pexmetinib                                  N-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[(5-fluoro-
                                             2-{[1-(2-hydroxyethyl)-1H-indazol-5-yl]oxy}phenyl)methyl]urea




                                                                                                                                               407
Recommended INN: List 72                                    WHO Drug Information, Vol. 28, No. 3, 2014




 pexmétinib                N-[3-tert-butyl-1-(4-méthylphényl)-1H-pyrazol-5-yl]-N'-[(5-fluoro-
                           2-{[1-(2-hydroxyéthyl)-1H-indazol-5-yl]oxy}phényl)méthyl]urée

 pexmetinib                N-[3-terc-butil-1-(4-metilfenil)-1H-pirazol-5-il]-N'-[(5-fluoro-
                           2-{[1-(2-hidroxietil)-1H-indazol-5-il]oxi}fenil)metil]urea

                           C31H33FN6O3

                                                                   CH3

                                        F


                                                H       H
                                                N       N     N
                                                                   N
                                        O           O
                                                                       CH3
                           N
                               N                                       CH3
                                                             H3C



                            HO




 pretomanidum
 pretomanid                (6S)-2-nitro-6-{[4-(trifluoromethoxy)phenyl]methoxy}-6,7-dihydro-
                           5H-imidazo[2,1-b][1,3]oxazine

 prétomanid                (6S)-2-nitro-6-{[4-(trifluorométhoxy)phényl]méthoxy}-6,7-dihydro-
                           5H-imidazo[2,1-b][1,3]oxazine

 pretomanid                (6S)-2-nitro-6-{[4-(trifluorometoxi)fenil]metoxi}-6,7-dihidro-
                           5H-imidazo[2,1-b][1,3]oxazina

                           C14H12F3N3O5

                                                                         O
                                                                             CF3
                                                    O
                                        N
                           O2N                      H
                                    N       O



 ralpancizumabum #
 ralpancizumab             immunoglobulin G2-kappa, anti-[Homo sapiens PCSK9 (proprotein
                           convertase subtilisin/kexin type 9, neural apoptosis-regulated
                           convertase 1, NARC1, NARC-1, proprotein convertase 9, PC9)],
                           humanized monoclonal antibody;
                           gamma2 heavy chain (1-444) [humanized VH (Homo sapiens
                           IGHV1-46*01 (91.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11]
                           (1-118) -Homo sapiens IGHG2*01 (CH1 (119-216), hinge (217-228),
                           CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS
                           (443-444)) (119-444)], (132-214')-disulfide with kappa light chain
                           (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-33*01
                           (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-
                           214')]; dimer (220-220":221-221":224-224":227-227")-
                           tetrakisdisulfide




408
WHO Drug Information, Vol. 28, No. 3, 2014                                                            Recommended INN: List 72


 ralpancizumab                               immunoglobuline G2-kappa, anti-[Homo sapiens PCSK9
                                             (proprotéine convertase subtilisine/kexine type 9, convertase 1
                                             régulée par l'apoptose neuronale, NARC1, NARC-1, proprotéine
                                             convertase 9, PC9)], anticorps monoclonal humanisé;
                                             chaîne lourde gamma2 (1-444) [VH humanisé (Homo sapiens
                                             IGHV1-46*01 (91.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11]
                                             (1-118) -Homo sapiens IGHG2*01 (CH1 (119-216), charnière (217-
                                             228), CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442),
                                             CHS (443-444)) (119-444)], (132-214')-disulfure avec la chaîne
                                             légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-
                                             33*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                                             (108'-214')]; dimère (220-220":221-221":224-224":227-227")-
                                             tétrakisdisulfure

 ralpancizumab                               inmunoglobulina G2-kappa, anti-[Homo sapiens PCSK9 (proproteína
                                             convertasa subtilisina/kexina tipo 9, convertasa 1 regulada por la
                                             apoptosis neuronal, NARC1, NARC-1, proproteína convertasa 9,
                                             PC9)], anticuerpo monoclonal humanizado;
                                             cadena pesada gamma2 (1-444) [VH humanizado (Homo sapiens
                                             IGHV1-46*01 (91.80%) -(IGHD)-IGHJ1*01 L123>T (113)) [8.8.11] (1-
                                             118) -Homo sapiens IGHG2*01 (CH1 (119-216), bisagra (217-228),
                                             CH2 A115>S (327), P116>S (328) (229-337), CH3 (338-442), CHS
                                             (443-444)) (119-444)], (132-214')-disulfuro con la cadena ligera
                                             kappa (1'-214') [V-KAPPA humanizado (Homo sapiens IGKV1-33*01
                                             (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-
                                             214')]; dímero (220-220":221-221":224-224":227-227")-
                                             tatrakisdisulfuro
                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVQSGAE VKKPGASVKV SCKASGYTFT                  SYYMHWVRQA       PGQGLEWMGE        50
                                             IHPSGGRTNY NEKFKSRVTM TRDTSTSTVY                  MELSSLRSED       TAVYYCARER       100
                                             PLYASDLWGQ GTTVTVSSAS TKGPSVFPLA                  PCSRSTSEST       AALGCLVKDY       150
                                             FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSNFGTQTYT       200
                                             CNVDHKPSNT KVDKTVERKC CVECPPCPAP                  PVAGPSVFLF       PPKPKDTLMI       250
                                             SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE                  VHNAKTKPRE       EQFNSTFRVV       300
                                             SVLTVVHQDW LNGKEYKCKV SNKGLPSSIE                  KTISKTKGQP       REPQVYTLPP       350
                                             SREEMTKNQV SLTCLVKGFY PSDIAVEWES                  NGQPENNYKT       TPPMLDSDGS       400
                                             FFLYSKLTVD KSRWQQGNVF SCSVMHEALH                  NHYTQKSLSL       SPGK             444

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIQMTQSPSS LSASVGDRVT ITCKASQDVH                  TAVAWYQQKP       GKAPKLLIYH 50
                                             ASYRYTGVPS RFSGSGSGTD FTFTISSLQP                  EDIATYYCQQ       RYSLWRTFGQ 100
                                             GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-96           145-201 258-318        364-422
                                                                    22''-96'' 145''-201'' 258''-318'' 364''-422''
                                             Intra-L (C23-C104) 23'-88'         134'-194'
                                                                    23'''-88''' 134'''-194'''
                                             Inter-H-L (CH1 10-CL 126)           132-214' 132''-214'''
                                             Inter-H-H (h 4, h 5, h 11, h 14) 220-220'' 221-221'' 224-224'' 227-227''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             294, 294''



 relamorelinum
 relamorelin                                 [3-(1-benzothiophen-3-yl)-N-(piperidin-4-ylcarbonyl)-D-alanyl]-
                                             D-tryptophyl-L-phenylalanyl-(4-aminopiperidine-4-carboxamide)

 rélamoréline                                [3-(1-benzothiophén-3-yl)-N-(pipéridin-4-ylcarbonyl)-D-alanyl]-
                                             D-tryptophyl-L-phénylalanyl-(4-aminopipéridine-4-carboxamide)

 relamorelina                                [3-(1-benzotiofen-3-il)-N-(piperidin-4-ilcarbonil)-D-alanil]-D-triptofil-
                                             L-fenilalanil-(4-aminopiperidina-4-carboxamida)




                                                                                                                                         409
Recommended INN: List 72                                      WHO Drug Information, Vol. 28, No. 3, 2014




                           C43H50N8O5S



                                                                   NH
                                                                                  H
                                                                                  N
                           HN                         O        H          O
                                           H                        H
                                           N                        N                       NH2
                                                          N                   N
                                                          H                   H
                                      O       H                 O         H           O


                                          S




 ribuvaptanum
 ribuvaptan                (2R)-2-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-
                           2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}acetamido)-
                           2-[3-(trifluoromethyl)phenyl]ethyl carbamate

 ribuvaptan                carbamate de (2R)-2-({3-(4-chlorophényl)-5-oxo-4-[(2S)-3,3,3-
                           trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-
                           1-yl}acétamido)-2-[3-(trifluorométhyl)phényl]éthyle

 ribuvaptán                carbamato de (2R)-2-({3-(4-clorofenil)-5-oxo-4-[(2S)-3,3,3-trifluoro-
                           2-hidroxipropil]-4,5-dihidro-1H-1,2,4-triazol-1-il}acetamido)- 2-[3-
                           (trifluorometil)fenil]etilo

                           C23H20ClF6N5O5

                                     F3C                            F3C

                                   HO
                                          H       N       O
                                                               O    H
                           Cl
                                                      N                       O       NH2
                                                  N                 N
                                                                    H
                                                                                  O



 samatasvirum
 samatasvir                methyl {(1R)-2-[(2S)-2-{4-[4-(6-{2-[(2S)-1-{(2S)-2-
                           [(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-
                           1H-benzimidazol-5-yl}thieno[3,2-b]thien-3-yl)phenyl]-1H-imidazol-
                           2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate

 samatasvir                {(1R)-2-[(2S)-2-{4-[4-(6-{2-[(2S)-1-{(2S)-2-[(méthoxycarbonyl)amino]-
                           3-méthylbutanoyl}pyrrolidin-2-yl]-1H-benzimidazol-5-yl}thiéno[3,2-
                           b]thién-3-yl)phényl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-
                           1-phényléthyl}carbamate de méthyle

 samatasvir                {(1R)-2-[(2S)-2-{4-[4-(6-{2-[(2S)-1-{(2S)-2-[(metoxicarbonil)amino]-
                           3-metilbutanoil}pirrolidin-2-il]-1H-benzoimidazol-5-il}tieno[3,2-b]tien-
                           3-il)fenil]-1H-imidazol-2-il}pirrolidin-1-il]-2-oxo-1-feniletil}carbamato
                           de metilo




410
WHO Drug Information, Vol. 28, No. 3, 2014                                                             Recommended INN: List 72


                                             C47H48N8O6S2
                                                                                                             H
                                                                                                             N H

                                                                 CH3                                         N         N
                                                             O
                                                                                                                 O
                                                                                                                           H
                                             H3 C       HN       O                   S                       O
                                                                 O                                                   NH
                                             H3 C H                                            S             O
                                                                 H     N
                                                             N                                                   CH3

                                                                       N
                                                                       H



 selinexorum
 selinexor                                   (2Z)-3-{3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl}-
                                             N'-(pyrazin-2-yl)prop-2-enehydrazide

 sélinexor                                   (2Z)-3-{3-[3,5-bis(trifluorométhyl)phényl]-1H-1,2,4-triazol-1-yl}-
                                             N'-(pyrazin-2-yl)prop-2-ènehydrazide

 selinexor                                   (2Z)-3-{3-[3,5-bis(trifluorometil)fenil]-1H-1,2,4-triazol-1-il}-N'-(pirazin-
                                             2-il)prop-2-enohidrazida

                                             C17H11F6N7O

                                                         CF3



                                                                       N                           N
                                             F 3C                              O     HN
                                                                  N N               NH         N




 sepetaprostum
 sepetaprost                                 propan-2-yl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-
                                             difluorophenoxy)-3-hydroxybut-1-en-1-yl]-7-hydroxyoctahydro-
                                             2H-cyclopenta[b]oxepin-3-yl}butanoate

 sépétaprost                                 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophénoxy)-
                                             3-hydroxybut-1-én-1-yl]-7-hydroxyoctahydro-
                                             2H-cyclopenta[b]oxépin-3-yl}butanoate de propan-2-yle

 sepetaprost                                 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorofenoxi)-
                                             3-hidroxibut-1-en-1-il]-7-hidroxioctahidro-2H-ciclopenta[b]oxepin-
                                             3-il}butanoato de propan-2-ilo

                                             C26H36F2O6

                                                         H
                                                                               O     CH3

                                                  O                        O       CH3
                                              H                                F
                                                             H

                                                                               O           F
                                             HO          H
                                                    H                H OH




                                                                                                                               411
Recommended INN: List 72                                 WHO Drug Information, Vol. 28, No. 3, 2014




 sofituzumabum vedotinum #
 sofituzumab vedotin         immunoglobulin G1-kappa auristatin E conjugate, anti-[Homo
                             sapiens MUC16 (mucin 16, MUC-16, cancer antigen 125, CA125)],
                             humanized monoclonal antibody conjugated to auristatin E;
                             gamma1 heavy chain (1-446) [humanized VH (Homo sapiens
                             IGHV3-48*03 (79.80%) -(IGHD)-IGHJ4*01) [9.8.9] (1-116) -Homo
                             sapiens IGHG1*03 (CH1 R120>K (213) (117-214), hinge (215-229),
                             CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-
                             214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA
                             (Homo sapiens IGKV1-5*01 (87.90%) -IGKJ1*01) [6.3.9] (1'-107') -
                             Homo sapiens IGKC*01 (108'-214')]; dimer (225-225":228-228")-
                             bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to
                             monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-
                             valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type
                             linker
                             For the vedotin part, please refer to the document "INN for pharmaceutical
                             substances: Names for radicals, groups and others"*.

 sofituzumab védotine        immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[Homo
                             sapiens MUC16 (mucine 16, MUC-16, antigène de cancer 125,
                             CA125)], anticorps monoclonal humanisé conjugué à l'auristatine E;
                             chaîne lourde gamma1 (1-446) [VH humanisé (Homo sapiens
                             IGHV3-48*03 (79.80%) -(IGHD)-IGHJ4*01) [9.8.9] (1-116) -Homo
                             sapiens IGHG1*03 (CH1 R120>K (213) (117-214), charnière (215-
                             229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)],
                             (219-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA
                             humanisé (Homo sapiens IGKV1-5*01 (87.90%) -IGKJ1*01) [6.3.9]
                             (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (225-
                             225":228-228")-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en
                             moyenne, au monométhylauristatine E (MMAE), via un linker clivable
                             de type maléimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl
                             (mc-val-cit-PABC)
                             Pour la partie védotine, veuillez-vous référer au document "INN for
                             pharmaceutical substances: Names for radicals, groups and others"*.

 sofituzumab vedotina        inmunoglobulina G1-kappa conjugada con la auristatina E, anti-
                             [Homo sapiens MUC16 (mucina 16, MUC-16, antígeno de cáncer
                             125, CA125)], anticuerpo monoclonal humanizado conjugado con la
                             auristatina E;
                             cadena pesada gamma1 (1-446) [VH humanizado (Homo sapiens
                             IGHV3-48*03 (79.80%) -(IGHD)-IGHJ4*01) [9.8.9] (1-116) -Homo
                             sapiens IGHG1*03 (CH1 R120>K (213) (117-214), bisagra (215-
                             229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)],
                             (219-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA
                             humanizada (Homo sapiens IGKV1-5*01 (87.90%) -IGKJ1*01)
                             [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (225-
                             225":228-228")-bisdisulfuro; conjugado, en una media de 3 a 4
                             restos cisteinil, con monometilauristatina E (MMAE), mediante un
                             conector separable de tipo maleimidocaproil-valil-citrulinil-
                             p-aminobencilloxicarbonilo (mc-val-cit-PABC)
                             Para la fracción vedotina pueden referirse al documento "INN for
                             pharmaceutical substances: Names for radicals, groups and others"*.




412
WHO Drug Information, Vol. 28, No. 3, 2014                                                                  Recommended INN: List 72



                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLVESGGG LVQPGGSLRL SCAASGYSIT                  NDYAWNWVRQ       APGKGLEWVG        50
                                             YISYSGYTTY NPSLKSRFTI SRDTSKNTLY                  LQMNSLRAED       TAVYYCARWT       100
                                             SGLDYWGQGT LVTVSSASTK GPSVFPLAPS                  SKSTSGGTAA       LGCLVKDYFP       150
                                             EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS                  LSSVVTVPSS       SLGTQTYICN       200
                                             VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA                  PELLGGPSVF       LFPPKPKDTL       250
                                             MISRTPEVTC VVVDVSHEDP EVKFNWYVDG                  VEVHNAKTKP       REEQYNSTYR       300
                                             VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP                  IEKTISKAKG       QPREPQVYTL       350
                                             PPSREEMTKN QVSLTCLVKG FYPSDIAVEW                  ESNGQPENNY       KTTPPVLDSD       400
                                             GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA                  LHNHYTQKSL       SLSPGK           446

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIQMTQSPSS LSASVGDRVT ITCKASDLIH                  NWLAWYQQKP       GKAPKLLIYG 50
                                             ATSLETGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       YWTTPFTFGQ 100
                                             GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-96          143-199       260-320   366-424
                                                                   22''-96'' 143''-199'' 260''-320'' 366''-424''
                                             Intra-L (C23-C104) 23'-88'         134'-194'
                                                                   23'''-88''' 134'''-194'''
                                             Inter-H-L (h 5-CL 126) * 219-214' 219''-214'''
                                             Inter-H-H (h 11, h 14) * 225-225'' 228-228''

                                             *Two or three of the inter-chain disulfide bridges are not present, an average of 3 to 4
                                             cysteinyl being conjugated each via a thioether bond to a drug linker.
                                             *Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 3 à 4 cystéinyl
                                             en moyenne étant chacun conjugué via une liaison thioéther à un linker.
                                             *Faltan dos o tres puentes disulfuro inter-catenarios, una media de 3 a 4 cisteinil está
                                             conjugada a conectores de principio activo.

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             296, 296''


 sotagliflozinum
 sotagliflozin                               methyl (5S)-5-C-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-1-thio-
                                             β-L-xylopyranoside

 sotagliflozine                              (5S)-5-C-{4-chloro-3-[(4-éthoxyphényl)méthyl]phényl}-1-thio-
                                             β-L-xylopyranoside de méthyle

 sotagliflozina                              (5S)-5-C-{4-cloro-3-[(4-etoxifenil)metil]fenil}-1-tio-β-L-xilopiranósido
                                             de metilo

                                             C21H25ClO5S

                                                         O       CH3




                                                                 Cl

                                             H3C
                                                     S
                                                             O
                                                     OH
                                               HO
                                                             OH

 taladegibum
 taladegib                                   4-fluoro-N-methyl-N-{1-[4-(1-methyl-1H-pyrazol-5-yl)phthalazin-
                                             1-yl]piperidin-4-yl}-2-(trifluoromethyl)benzamide

 taladégib                                   4-fluoro-N-méthyl-N-{1-[4-(1-méthyl-1H-pyrazol-5-yl)phtalazin-
                                             1-yl]pipéridin-4-yl}-2-(trifluorométhyl)benzamide

 taladegib                                   4-fluoro-N-metil-N-{1-[4-(1-metil-1H-pirazol-5-il)ftalazin-1-il]piperidin-
                                             4-il}-2-(trifluorometil)benzamida



                                                                                                                                               413
Recommended INN: List 72                                     WHO Drug Information, Vol. 28, No. 3, 2014




                           C26H24F4N6O

                           F
                                                 CH3
                                                 N

                                     CF3     O           N        N
                                                                      N   CH3
                                                                          N
                                                                              N




 talazoparibum
 talazoparib               (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-
                           5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one

 talazoparib               (8S,9R)-5-fluoro-8-(4-fluorophényl)-9-(1-méthyl-1H-1,2,4-triazol-
                           5-yl)-2,7,8,9-tétrahydro-3H-pyrido[4,3,2-de]phtalazin-3-one

 talazoparib               (8S,9R)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1H-1,2,4-triazol-5-il)-
                           2,7,8,9-tetrahidro-3H-pirido[4,3,2-de]ftalazin-3-ona


                           C19H14F2N6O

                                                     H
                                                     N   O
                                         N       N
                                 N
                                     N
                               H3C       H
                                               N              F
                                             H H
                           F



 tilapertinum
 tilapertin                (4-{(R)-phenyl[3-(trifluoromethyl)phenyl]methyl}piperazin-1-yl)acetic
                           acid

 tilapertine               acide (4-{(R)-phényl[3-(trifluorométhyl)phényl]méthyl}pipérazin-
                           1-yl)acétique

 tilapertina               ácido (4-{(R)-fenil[3-(trifluorometil)fenil]metil}piperazin-1-il)acético

                           C20H21F3N2O2

                                                         N        CO2H
                                                     N
                           F3C
                                             H




414
WHO Drug Information, Vol. 28, No. 3, 2014                                                              Recommended INN: List 72




 ulocuplumabum #
 ulocuplumab                                 immunoglobulin G4-kappa, anti-[Homo sapiens CXCR4 (chemokine
                                             (C-X-C motif) receptor 4, fusin, stromal cell-derived factor 1 receptor,
                                             SDF-1 receptor, CXCL12 receptor, CD184)], human monoclonal
                                             antibody;
                                             gamma4 heavy chain (1-451) [Homo sapiens VH (IGHV3-48*02
                                             (96.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126-
                                             223), hinge S10>P (233) (224-235), CH2 (236-345), CH3 (346-450),
                                             CHS K2>del (451)) (126-451)], (139-214')-disulfide with kappa light
                                             chain (1'-214') [Homo sapiens (V-KAPPA (IGKV1D-16*01 (98.90%) -
                                             IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (231-
                                             231":234-234")-bisdisulfide

 ulocuplumab                                 immunoglobuline G4-kappa, anti-[Homo sapiens CXCR4 (récepteur
                                             4 de chimiokine (C-X-C motif), fusine, récepteur du facteur 1 dérivé
                                             des cellules stromales, récepteur du SDF-1, récepteur du CXCL12,
                                             CD184)], anticorps monoclonal humain;
                                             chaîne lourde gamma4 (1-451) [Homo sapiens VH (IGHV3-48*02
                                             (96.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126-
                                             223), charnière S10>P (233) (224-235), CH2 (236-345), CH3 (346-
                                             450), CHS K2>del (451)) (126-451)], (139-214')-disulfure avec la
                                             chaîne légère kappa (1'-214') [Homo sapiens (V-KAPPA (IGKV1D-
                                             16*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')];
                                             dimère (231-231":234-234")-bisdisulfure

 ulocuplumab                                 inmunoglobulina G4-kappa, anti-[Homo sapiens CXCR4 (receptor 4
                                             de quimiokina (C-X-C motif), fusina, receptor del factor 1 derivado de
                                             células estromales, receptor del SDF-1, receptor del CXCL12,
                                             CD184)], anticuerpo monoclonal humano;
                                             cadena pesada gamma4 (1-451) [Homo sapiens VH (IGHV3-48*02
                                             (96.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126-
                                             223), bisagra S10>P (233) (224-235), CH2 (236-345), CH3 (346-
                                             450), CHS K2>del (451)) (126-451)], (139-214')-disulfuro con la
                                             cadena ligera kappa (1'-214') [Homo sapiens (V-KAPPA (IGKV1D-
                                             16*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')];
                                             dímero (231-231":234-234")-bisdisulfuro


                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLVESGGG LVQPGGSLRL SCAAAGFTFS                  SYSMNWVRQA       PGKGLEWVSY        50
                                             ISSRSRTIYY ADSVKGRFTI SRDNAKNSLY                  LQMNSLRDED       TAVYYCARDY       100
                                             GGQPPYYYYY GMDVWGQGTT VTVSSASTKG                  PSVFPLAPCS       RSTSESTAAL       150
                                             GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA                  VLQSSGLYSL       SSVVTVPSSS       200
                                             LGTKTYTCNV DHKPSNTKVD KRVESKYGPP                  CPPCPAPEFL       GGPSVFLFPP       250
                                             KPKDTLMISR TPEVTCVVVD VSQEDPEVQF                  NWYVDGVEVH       NAKTKPREEQ       300
                                             FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN                  KGLPSSIEKT       ISKAKGQPRE       350
                                             PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS                  DIAVEWESNG       QPENNYKTTP       400
                                             PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC                  SVMHEALHNH       YTQKSLSLSL       450
                                             G                                                                                   451

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIQMTQSPSS LSASVGDRVT ITCRASQGIS                  SWLAWYQQKP       EKAPKSLIYA 50
                                             ASSLQSGVPS RFSGSGSGTD FTLTISSLQP                  EDFVTYYCQQ       YNSYPRTFGQ 100
                                             GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-96          152-208       266-326   372-430
                                                                   22''-96'' 152''-208'' 266''-326'' 372''-430''
                                             Intra-L (C23-C104) 23'-88'         134'-194'
                                                                   23'''-88''' 134'''-194'''
                                             Inter-H-L (CH1 10-CL 126) 139-214' 139''-214'''
                                             Inter-H-H (h 8, h 11)            231-231'' 234-234''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             302, 302''




                                                                                                                                               415
Recommended INN: List 72                                   WHO Drug Information, Vol. 28, No. 3, 2014


 veledimexum
 veledimex                 N'-(3,5-dimethylbenzoyl)-N'-[(3R)-2,2-dimethylhexan-3-yl]-2-ethyl-
                           3-methoxybenzohydrazide

 vélédimex                 N'-(3,5-diméthylbenzoyl)-N'-[(3R)-2,2-diméthylhexan-3-yl]-2-éthyl-
                           3-méthoxybenzohydrazide

 veledimex                 N'-(3,5-dimetilbenzoil)-N'-[(3R)-2,2-dimetilhexan-3-il]-2-etil-
                           3-metoxibenzohidrazida

                           C27H38N2O3

                                                       CH3     OCH3

                                           O
                                                   H
                           H3C                     N
                                               N
                                                       O
                                                   H
                                                       CH3
                                    CH3
                                                       CH3
                                     H3C    H3C


 verdinexorum
 verdinexor                (2Z)-3-{3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl}-
                           N'-(pyridin-2-yl)prop-2-enehydrazide

 verdinexor                (2Z)-3-{3-[3,5-bis(trifluorométhyl)phényl]-1H-1,2,4-triazol-1-yl}-
                           N'-(pyridin-2-yl)prop-2-ènehydrazide

 verdinexor                (2Z)-3-{3-[3,5-bis(trifluorometil)fenil]-1H-1,2,4-triazol-1-il}-N'-(piridin-
                           2-il)prop-2-enohidrazida

                           C18H12F6N6O

                                    CF3



                                               N
                           F3C                         O     HN
                                           N N               NH    N



 zastumotidum #
 zastumotide               19,137,308,342,395-penta[S-(2-amino-2-oxoethyl)]-{[2-aspartic
                                  2               3
                           acid(K >D),3-proline(L >P)]glycerophosphoryl diester
                           phosphodiesterase (Haemophilus influenzae strain 86-028NP EC
                           3.1.4.46)-(1-127)-peptide fusion protein with [2-aspartic
                                  2
                           acid(P >D)]human melanoma-associated antigen 3 (MAGE-3
                           antigen, antigen MZ2-D, cancer/testis antigen 1.3 or CT1.3) fusion
                           protein with diglycylheptahistidine}

 zastumotide               19,137,308,342,395-penta[S-(2-amino-2-oxoéthyl)]-{[2-acide
                                        2               3
                           aspartique(K >D),3-proline(L >P)]phosphodiestérase du diester de
                           glycérophosphoryle (Haemophilus influenzae souche 86-028NP EC
                           3.1.4.46)-(1-127)-peptide, protéine de fusion avec le [2-acide
                                        2
                           aspartique(P >D)]antigène 3 humain associé au mélanome
                           (antigène MAGE-3, antigène MZ2-D, antigen 1.3 associé au cancer
                           des testicules ou CT1.3) protéine de fusion avec la
                           diglycylheptahistidine}




416
WHO Drug Information, Vol. 28, No. 3, 2014                                                                    Recommended INN: List 72


 zastumotida                                     19,137,308,342,395-penta[S-(2-amino-2-oxoetil)]-{[2-ácido
                                                              2              3
                                                 aspártico(K >D),3-prolina(L >P)]fosfodiestarasa del diéster de
                                                 glicerofosforilo (Haemophilus influenzae cepa 86-028NP EC
                                                 3.1.4.46)-(1-127)-péptido, proteína de fusión con el [2-ácido
                                                              2
                                                 aspártico(P >D)]antígeno 3 humano asociado al melanoma
                                                 (antígeno MAGE-3, antígeno MZ2-D, antígeno 1.3 asociado al
                                                 cáncer de testículos o CT1.3) proteína de fusión con la
                                                 diglicilheptahistidina}


                                                 MDPKTLALSL        LAAGVLAGCS        SHSSNMANTQ         MKSDKIIIAH     RGASGYLPEH   50
                                                 TLESKALAFA        QQADYLEQDL        AMTKDGRLVV         IHDHFLDGLT     DVAKKFPHRH   100
                                                 RKDGRYYVID        FTLKEIQSLE        MTENFETMDL         EQRSQHCKPE     EGLEARGEAL   150
                                                 GLVGAQAPAT        EEQEAASSSS        TLVEVTLGEV         PAAESPDPPQ     SPQGASSLPT   200
                                                 TMNYPLWSQS        YEDSSNQEEE        GPSTFPDLES         EFQAALSRKV     AELVHFLLLK   250
                                                 YRAREPVTKA        EMLGSVVGNW        QYFFPVIFSK         ASSSLQLVFG     IELMEVDPIG   300
                                                 HLYIFATCLG        LSYDGLLGDN        QIMPKAGLLI         IVLAIIAREG     DCAPEEKIWE   350
                                                 ELSVLEVFEG        REDSILGDPK        KLLTQHFVQE         NYLEYRQVPG     SDPACYEFLW   400
                                                 GPRALVETSY        VKVLHHMVKI        SGGPHISYPP         LHEWVLREGE     EGGHHHHHHH   450
                                                  Modified residues / Résidus modifiés / Restos modificados
                                                               C
                                                      19-137-308-342-395                    O           H     NH2
                                                 S-(2-amino-2-oxoethyl)cysteine                    S
                                                                                      H2N                      CO2H




# Electronic structure available on Mednet: http://mednet.who.int/
# Structure électronique disponible sur Mednet: http://mednet.who.int/
# Estructura electrónica disponible en Mednet: http://mednet.who.int/
 
* http://www.who.int/entity/medicines/services/inn/Radical_Book_2012.pdf



                                                                                                                                     417
Recommended INN: List 72                                                       WHO Drug Information, Vol. 28, No. 3, 2014




                            AMENDMENTS TO PREVIOUS LISTS
                    MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                        MODIFICACIONES A LAS LISTAS ANTERIORES
Dénominations communes internationales recommandées (DCI Rec.): Liste 4
(Chron. Org. mond. Santé, Vol. 16, No. 3, 1962)

p. 120         penicillinasum
               pénicillinase           remplacer la description par la suivante
                                       enzyme obtenue par fermentation à partir de cultures de Bacillus cereus

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 29
(Información Farmacéutica de la OMS, Vol. 3, No. 3, 1989)
p. 2            suprimáse               insertese
                atosiban                atosibán


Recommended International Non Proprietary Names (Rec. INN): List 58
Dénominations communes internationales recommandées (DCI Rec.): Liste 58
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 58
(WHO Drug Information, Vol. 21, No. 3, 2007)

p. 255         delete/supprimer/suprimáse          insert/insérer/insertese
               methylnaltrexonii bromidum          methylnaltrexoni bromidum
               bromure de méthylnaltrexone         remplacer le nom chimique et la structure par les suivants
               bromuro de metilnaltrexona          sustitúyase el nombre químico y la estructura por los siguientes

                                        bromure de (17R)-17-(cyclopropylméthyl)-4,5-époxy-
                                        3,14-dihydroxy-17-méthyl-6-oxomorphinanium

                                        bromuro de (17R)-17-(ciclopropilmetil)-4,5-epoxi-3,14-dihidroxi-17-metil-
                                        6-oxomorfinanio

                                                                CH3
                                                   H       N+

                                                   HO                   Br-



                                        HO          O               O
                                                           H

Recommended International Non Proprietary Names (Rec. INN): List 66
Dénominations communes internationales recommandées (DCI Rec.): Liste 66
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 66
(WHO Drug Information, Vol. 25, No. 3, 2011)

p. 307         egaptivonum pegolum
               egaptivon pegol         replace the structure by the following
               égaptivon pégol         remplacer la structure par la suivante
               egaptivón pegol         sustitúyase la estructura por la siguiente

                                       (3'-5')-(R-p-Gm-Cm-Gm-Um-dG-dC-dA-Gm-Um-Gm-Cm-Cm-
                                       Um-Um-Cm-Gm-Gm-Cm-dC-Gm-sp-dT-Gm-dC-dG-dG-dT-
                                       Gm-Cm-dC-Um- dC-dC-Gm-Um-dC-Am-Cm-Gm-Cm3'-3'dT)
                                       Legend:
                                       d = 2'-deoxy
                                       m = 2'-O-methyl
                                       -sp- = P-thiophosphate
                                       R p     =           O
                                       H3CO                                   O   O
                                                       O        N               P   (C5')
                                                           n    H
                                                                               O OH




418
WHO Drug Information, Vol. 28, No. 3, 2014                                                                         Recommended INN: List 72




Recommended International Non Proprietary Names (Rec. INN): List 69
Dénominations communes internationales recommandées (DCI Rec.): Liste 69
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 69
(WHO Drug Information, Vol. 27, No. 1, 2013)

p. 42         actoxumabum #
              actoxumab             replace the description and the structure by the following ones
              actoxumab             remplacer la description et la structure par les suivantes
              actoxumab             sustitúyase las descripción y la estructura por las siguientes

                                    immunoglobulin G1-kappa, anti-[Clostridium difficile toxin A], Homo sapiens
                                    monoclonal antibody;
                                    gamma1 heavy chain (1-452) [Homo sapiens VH (IGHV3-33*01 (93.90%) -(IGHD)-
                                    IGHJ3*02) [8.8.15] (1-122) -IGHG1*03 (CH1 (123-220), hinge (221-235), CH2 (236-
                                    345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfide with kappa
                                    light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (98.90%) -IGKJ1*01)
                                    [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (231-231'':234-234'')-bisdisulfide

                                    immunoglobuline G1-kappa, anti-[Clostridium difficile toxine A], Homo sapiens
                                    anticorps monoclonal;
                                    chaîne lourde gamma1 (1-452) [Homo sapiens VH (IGHV3-33*01 (93.90%) -(IGHD)-
                                    IGHJ3*02) [8.8.15] (1-122) -IGHG1*03 (CH1 (123-220), charnière (221-235), CH2
                                    (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfure avec la
                                    chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (98.90%) -
                                    IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (231-231'':234-234'')-
                                    bisdisulfure

                                    inmunoglobulina G1-kappa, anti-[Clostridium difficile toxina A], anticuerpo monoclonal
                                    de Homo sapiens;
                                    cadena pesada gamma1 (1-452) [Homo sapiens VH (IGHV3-33*01 (93.90%) -
                                    (IGHD)-IGHJ3*02) [8.8.15] (1-122) -IGHG1*03 (CH1 (123-220), bisagra (221-235),
                                    CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfuro con
                                    la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (98.90%) -
                                    IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (231-231'':234-234'')-
                                    bisdisulfuro

                                    Heavy chain / Chaîne lourde / Cadena pesada
                                    QVQLVESGGG VVQPGRSLRL SCAASGFSFS                  NYGMHWVRQA       PGKGLEWVAL        50
                                    IWYDGSNEDY TDSVKGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYYCARWG       100
                                    MVRGVIDVFD IWGQGTVVTV SSASTKGPSV                  FPLAPSSKST       SGGTAALGCL       150
                                    VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ                  SSGLYSLSSV       VTVPSSSLGT       200
                                    QTYICNVNHK PSNTKVDKRV EPKSCDKTHT                  CPPCPAPELL       GGPSVFLFPP       250
                                    KPKDTLMISR TPEVTCVVVD VSHEDPEVKF                  NWYVDGVEVH       NAKTKPREEQ       300
                                    YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN                  KALPAPIEKT       ISKAKGQPRE       350
                                    PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS                  DIAVEWESNG       QPENNYKTTP       400
                                    PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC                  SVMHEALHNH       YTQKSLSLSP       450
                                    GK                                                                                  452

                                    Light chain / Chaîne légère / Cadena ligera
                                    DIQMTQSPSS VSASVGDRVT ITCRASQGIS                  SWLAWYQHKP       GKAPKLLIYA 50
                                    ASSLQSGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       ANSFPWTFGQ 100
                                    GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                    DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                    LSSPVTKSFN RGEC                                                               214

                                    Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                    Intra-H (C23-C104) 22-96         149-205 266-326 372-430
                                                          22''-96'' 149''-205'' 266''-326'' 372''-430''
                                    Intra-L (C23-C104) 23'-88' 134'-194'
                                                         23'''-88''' 134'''-194'''
                                    Inter-H-L (h 5-CL 126) 225-214' 225''-214'''
                                    Inter-H-H (h 11, h 14) 231-231'' 234-234''

                                    N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                    H CH2 N84.4:
                                    302, 302''




                                                                                                                                        419
Recommended INN: List 72                                              WHO Drug Information, Vol. 28, No. 3, 2014


p. 51         crisantaspasum #
              crisantaspase      replace the description and the structure by the following ones
              crisantaspase      remplacer la description et la structure par les suivantes
              crisantaspasa      sustitúyase la descripción y la estructura por las siguientes

                                 L-asparaginase (EC 3.5.1.1, L-asparagine amidohydrolase) Erwinia
                                 chrysanthemi (Dickeya dadantii, Pectobacterium chrysanthemi) tetramer α4

                                 L-asparaginase (EC 3.5.1.1, L-asparagine amidohydrolase) Erwinia
                                 chrysanthemi (Dickeya dadantii, Pectobacterium chrysanthemi), tétramère α4

                                 L-asparaginasa (EC 3.5.1.1, L-asparagina amidohidrolasa) de Erwinia
                                 chrysanthemi (Dickeya dadantii, Pectobacterium chrysanthemi), tetrámero α4

                                 Monomer / Monomère / Monómero
                                 ADKLPNIVIL ATGGTIAGSA ATGTQTTGYK          AGALGVDTLI   NAVPEVKKLA    50
                                 NVKGEQFSNM ASENMTGDVV LKLSQRVNEL          LARDDVDGVV   ITHGTDTVEE   100
                                 SAYFLHLTVK SDKPVVFVAA MRPATAISAD          GPMNLLEAVR   VAGDKQSRGR   150
                                 GVMVVLNDRI GSARYITKTN ASTLDTFKAN          EEGYLGVIIG   NRIYYQNRID   200
                                 KLHTTRSVFD VRGLTSLPKV DILYGYQDDP          EYLYDAAIQH   GVKGIVYAGM   250
                                 GAGSVSVRGI AGMRKAMEKG VVVIRSTRTG          NGIVPPDEEL   PGLVSDSLNP   300
                                 AHARILLMLA LTRTSDPKVI QEYFHTY                                       327

p. 68         nivolumabum #
              nivolumab          replace the description by the following
              nivolumab          remplacer la description par la suivante
              nivolumab          sustitúyase la descripción por la siguiente

                                 immunoglobulin G4-kappa, anti-[Homo sapiens PDCD1 (programmed cell
                                 death 1, PD-1, PD1, CD279)], Homo sapiens monoclonal antibody;
                                 gamma4 heavy chain (1-440) [Homo sapiens VH (IGHV3-33*01 (91.80%) -
                                 (IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 hinge S10>P (221) (114-440)],
                                 (127-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA
                                 (IGKV3-11*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')];
                                 (219-219'':222-222'')-bisdisulfide dimer

                                 immunoglobuline G4-kappa, anti-[Homo sapiens PDCD1 (protéine 1 de mort
                                 cellulaire programmée, PD-1, PD1, CD279)], Homo sapiens anticorps
                                 monoclonal;
                                 chaîne lourde gamma4 (1-440) [Homo sapiens VH (IGHV3-33*01 (91.80%) -
                                 (IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 charnière S10>P (221) (114-
                                 440)], (127-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens
                                 V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-
                                 214')]; dimère (219-219'':222-222'')-bisdisulfure

                                 inmunoglobulina G4-kappa, anti-[PDCD1 de Homo sapiens (proteína 1 de
                                 muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal de
                                 Homo sapiens;
                                 cadena pesada gamma4 (1-440) [Homo sapiens VH (IGHV3-33*01 (91.80%) -
                                 (IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 bisagra S10>P (221) (114-440)],
                                 (127-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens
                                 V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-
                                 214')]; dímero (219-219'':222-222'')-bisdisulfuro


p. 77-78      rovatirelinun
              rovatirelin        replace the chemical name by the following
              rovatiréline       remplacer le nom chimique par le suivant
              rovatirelina       sustitúyase el nombre químico por el siguiente

                                 (4S,5S)-5-methyl-N-{(2S)-1-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-3-(1,3-thiazol-
                                 4-yl)propan-2-yl}-2-oxo-1,3-oxazolidine-4-carboxamide




420
WHO Drug Information, Vol. 28, No. 3, 2014                                                         Recommended INN: List 72


                                        (4S,5S)-5-méthyl-N-{(2S)-1-[(2R)-2-méthylpyrrolidin-1-yl]-1-oxo-3-(1,3-thiazol-
                                        4-yl)propan-2-yl}-2-oxo-1,3-oxazolidine-4-carboxamide

                                        (4S,5S)-5-metil-N-{(2S)-1-[(2R)-2-metilpirrolidin-1-il]-1-oxo-3-(1,3-tiazol-
                                        4-il)propan-2-il}-2-oxo-1,3-oxazolidina-4-carboxamida



Recommended International Non Proprietary Names (Rec. INN): List 70
Dénominations communes internationales recommandées (DCI Rec.): Liste 70
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 70
(WHO Drug Information, Vol. 27, No. 3, 2013)

p. 291         filgotinibum
               filgotinib               replace the chemical name by the following
               filgotinib               remplacer le nom chimique par le suivant
               filgotinib               sustitúyase el nombre químico por el siguiente
                                                              6
                                        N-(5-{4-[(1,1-dioxo-λ -thiomorpholin-4-yl)methyl]phenyl}[1,2,4]triazolo[1,5-
                                        a]pyridin-
                                        2-yl)cyclopropanecarboxamide
                                                              6
                                        N-(5-{4-[(1,1-dioxo-λ -thiomorpholin-4-yl)méthyl]phényl}[1,2,4]triazolo[1,5-
                                        a]pyridin-2-yl)cyclopropanecarboxamide
                                                              6
                                        N-(5-{4-[(1,1-dioxo-λ -tiomorfolin-4-il)metil]fenil}[1,2,4]triazolo[1,5-a]piridin-
                                        2-il)ciclopropanocarboxamida

p. 320         delete/supprimer/suprimáse          insert/insérer/insertese
               methylnaltrexonii bromidum          methylnaltrexoni bromidum
               methylnaltrexone bromide            replace the chemical name by the following one

                                       (17R)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-
                                       6-oxomorphinanium bromide


Recommended International Non Proprietary Names (Rec. INN): List 71
Dénominations communes internationales recommandées (DCI Rec.): Liste 71
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 71
(WHO Drug Information, Vol. 28, No. 1, 2014)

p. 94          mavatrepum
               mavatrep                 replace the chemical name by the following
               mavatrep                 remplacer le nom chimique par le suivant
               mavatrep                 sustitúyase el nombre químico por el siguiente

                                        2-[2-(2-{(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1H-benzimidazol-
                                        5-yl)phenyl]propan-2-ol

                                        2-[2-(2-{(1E)-2-[4-(trifluorométhyl)phényl]éthényl}-1H-benzimidazol-
                                        5-yl)phényl]propan-2-ol

                                        2-[2-(2-{(1E)-2-[4-(trifluorometil)fenil]etenil}-1H-benzoimidazol-5-il)fenil]propan-
                                        2-ol

p. 106         roniciclibum
               roniciclib               replace the chemical name by the following
               roniciclib               remplacer le nom chimique par le suivant
               roniciclib               sustitúyase el nombre químico por el siguiente

                                        (R)-cyclopropyl(4-{[4-{[(2R,3R)-3-hydroxybutan-2-yl]oxy}-
                                                                                              6
                                        5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)imino-λ -sulfanone


                                                                                                                               421
 Recommended INN: List 72                                                      WHO Drug Information, Vol. 28, No. 3, 2014




                                        (R)-cyclopropyl(4-{[4-{[(2R,3R)-3-hydroxybutan-2-yl]oxy}-
                                                                                              6
                                        5-(trifluorométhyl)pyrimidin-2-yl]amino}phényl)imino-λ -sulfanone

                                        (R)-ciclopropil(4-{[4-{[(2R,3R)-3-hidroxibutan-2-il]oxi}-5-(trifluorometil)pirimidin-
                                                                 6
                                        2-il]amino}fenil)imino-λ -sulfanona


 p. 111         topsalysinum #
                topsalysin              replace the description by the following
                topsalysine             remplacer la description par la suivante
                topsalisina             sustitúyase la descripción por la siguiente

                                        recombinant DNA derived proaerolysin, pore-forming protein, from Aeromonas
                                        hydrophila, with the furin site substituted with a prostate specific antigen (PSA)
                                        cleavage site, fusion protein with 6 histidines, produced in Escherichia coli
                                        (nonglycosylated):
                                        [427-L-histidine(K>H),428-L-serine(V>S),429-L-serine(R>S),430-L-
                                        lysine(R>K),431-L-leucine(A>L),432-L-glutamine(R>Q)]proaerolysin Aeromonas
                                        hydrophila fusion protein with hexa-L-histidine

                                        proaérolysine, protéine formant des pores, d'Aeromonas hydrophila dont le site
                                        furine est substitué par le site de clivage reconnu par l'antigène prostatique
                                        spécifique (APS), protéine de fusion avec 6 histidines, produite par Escherichia
                                        coli à partir d'ADN recombinant (non glycosylée) :
                                        [427-L-histidine(K>H),428-L-sérine(V>S),429-L-sérine(R>S),430-L-
                                        lysine(R>K),431-L-leucine(A>L),432-L-glutamine(R>Q)]proaérolysine
                                        d'Aeromonas hydrophila protéine de fusion avec l'hexa-L-histidine

                                        proaerolisina, proteína formadora de poros, d'Aeromonas hydrophila cuyo sitio
                                        furina está substituido por el sitio de clivaje reconocido por el antígeno
                                        prostático específico, proteína de fusión con 6 histidinas, producida por
                                        Escherichia coli a partir de ADN recombinante (no glicosilada) :
                                        [427-L-histidina(K>H),428-L-serina(V>S),429-L-serina (R>S),430-L-
                                        lisina(R>K),431-L-leucina(A>L),432-L-glutamina(R>Q)]proaerolisina
                                        d'Aeromonas hydrophila proteina de fusión con hexa-L-histidina




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




 422
